

Curriculum Vita and Bibliography of Pat Zanzonico, PhD, DABRNAME AND GENERAL INFORMATION

<i>Name</i>	Pat Zanzonico
<i>Current positions</i>	Attending Physicist and Member Departments of Medical Physics and Radiology (Molecular imaging and Therapy Service) Co-Head, Small-Animal Imaging Core Facility Memorial Sloan-Kettering Cancer Center
<i>Professional address</i>	Memorial Sloan-Kettering Cancer Center 1275 York Avenue New York, NY 10021
<i>Telephone no</i>	(646) 888-2134
<i>Cell telephone no</i>	(516) 270-5894
<i>FAX no</i>	(212) 717-3442
<i>E Mail</i>	ZANZONIP@MSKCC.ORG
<i>Pager ID</i>	2487
<i>Longer distance pager</i>	(91) 649-2433
<i>Permit</i>	New York City Fire Department C-14 Certificate of Fitness Charge of Chemical Laboratory

EDUCATIONAL BACKGROUND

Cooper Union, School of Engineering and Science, New York, NY	BS (Physics)	1973-77
Cornell University, Graduate School of Medical Sciences, New York, NY	PhD (Biophysics)	1977-82

BOARD CERTIFICATION

Nuclear Medical Physics
American Board of Radiology (ABR), ID # P6456

PROFESSIONAL LICENSURE

Medical Physics - Medical Nuclear Physics
New York State License No 000036

PROFESSIONAL POSITIONS

Academic Positions

Assistant Professor of Radiology
July 1984 - June 1989
Associate Professor of Physics in Radiology
July 1989 -
Cornell University Medical College
New York, NY

Associate Professor on the Special Contributing Faculty
Gerstner Sloan-Kettering Graduate School
Memorial Sloan-Kettering Cancer Center
New York, NY
2007-

Hospital and Research Positions

Research Associate
May 1982 - September 1984
Assistant Laboratory Member
September 1984 - September 1986
Biophysics Laboratory
Sloan-Kettering Institute for Cancer Research
New York, NY

Assistant Attending Physicist
July 1984 - June 1989

Attending Physicist
July 1989 – June 1998

Division of Nuclear Medicine
Department of Radiology
The New York Hospital
New York, NY

Attending Physicist and Member
Head, Small-Animal Imaging Core Facility (microPET, microCT,
microSPECT, Optical Imager)
July 1998 - (promoted to current positions in 2011)
Memorial Sloan-Kettering Cancer Center
New York, NY

APPOINTMENTS, DUTIES, AND RESPONSIBILITIES

Technical Assistant
Task Group on Health Physics and Dosimetry
President's Commission on the Accident at Three Mile Island
June - September 1979

Faculty (Radiation Biology)
School of Radiation Oncology Technology
Memorial Hospital for Cancer and Allied Diseases
New York, NY
September 1979 - July 1988

Reviewer
American Cancer Society Institutional Grant
Sloan-Kettering Institute for Cancer Research
New York, NY
1982

Research Collaborator
Medical Department
Brookhaven National Laboratory
Upton, NY
September 1983 - September 1988

Reviewer
Cancer Investigation
1984

Reviewer
Journal of Nuclear Medicine
1984, 1992 -

Member
Radiobiology Committee
Greater New York Chapter of the Society of Nuclear Medicine
1984 -

Faculty Sponsor (with Dr. Rodney Bigler)
Special Summer Fellowship Research Program
Cornell University Medical College
New York, NY
1985 - 92

Faculty (Physics and Radiation Biology)
The Institute of Allied Medical Professions
New York, NY
1986 -

Reviewer
Health Physics
1986, 1990, 1992

Member
Nuclear Medicine Task Group 2 ("Dosimetry of Radiolabeled Antibodies")
American Association of Physicists in Medicine
1987 -

Ad hoc reviewer (with Dr. Jae Ho Kim)
Grant Application
National Institutes of Health
1987

Member
Joint Committee on Information Management
New York Hospital-Cornell Medical Center
New York, NY
1987 - 1998

Member
Various sub-committees/task forces
Medical Internal Radionuclide Dosimetry (MIRD) Committee
Society of Nuclear Medicine
1988 -

Co-Director (Biophysics Core Laboratory); Internal Advisory Committee
Clinical Nutrition Research Unit
Memorial Sloan-Kettering Cancer Center
New York, NY
1988 - 1993

Reviewer
International Journal of Radiation Oncology Biology and Physics
1988

Reviewer
Journal of the American Medical Association
1990

Consulting Physicist
The 407 Medical Associates
407 East 70th Street
New York, NY 10021
1990-1994

Reviewer, Scientific Session Moderator, and Sub-Chairman
Dosimetry/Radiobiology section
Annual Society of Nuclear Medicine National Meeting
1990 - 1992, 2002, 2003

Reviewer (Book)
Clinical Imaging
1990, 1992

Reviewer
Cancer Research
1992

Reviewer
Merit Review Application
Veterans Health and Services and Research Administration (VA)
Department of Veterans Affairs
1992

Reviewer
Conference Proposal
New York Academy of Sciences
1992

Examiner
RAPHEX Examination
Radiological and Medical Physics Society (RAMPS)
1992, 1998, 2004

Reviewer/Associate Editor
Medical Physics
1992, 1993, 1998

Fellow, Steering Committee Member At Large, and Secretary
Nuclear Medicine Section
New York Academy of Medicine
1995 -

Member
National Council on Radiation Protection and Measurements (NCRP)
Scientific Committee 91-1
1995 -
Scientific Committee 1-8
1997 -
Council
2000 -

Reviewer
Grant application
Ohio Cancer Research Associates
1995, 1999

Associate Editor
Journal of Nuclear Medicine
1996 - 98, 2001-

Organizer, Continuing Education Sessions
1998 Annual Meeting of the Society of Nuclear Medicine - "Revised NRC Regulations"
Toronto, Canada
2004 Annual Meeting of the Society of Nuclear Medicine - "Small-Animal Imaging"
and "Routine QC"
Philadelphia, PA
2004 Annual Meeting of the Society of Nuclear Medicine - "Ethics in Research"
New Orleans, LA

Faculty, Nuclear Medicine Physics, Equipment and Computers, Safety, and Regulatory Issues
Annual Radiologic Physics Review Course for Radiology Residents
IHD of NJ Medical Physics Consulting
Hasbrouck Heights
1998-

Expert Consultant
Coordinated Research Project (CRP), Management of Liver Cancer Using Radionuclide Methods with Special Emphasis on Early Diagnosis, Locoregional Therapy (Intra-Arterial) and Internal Dosimetry
International Atomic Energy Agency (IAEA)
2000-

Organizer, Continuing Education Session on "Gamma Camera Quality Control" and on "Small-Animal Imaging"
2004 Annual Meeting of the Society of Nuclear Medicine
Philadelphia, PA
2004

Member, Committee on Radiation (Chairman, Non-Human Use Sub-Committee)
Memorial Sloan-Kettering Cancer Center
New York, NY
2002-
Chairman, 2008-

Member, Radioactive Drug Research Committee (RDRC)
Memorial Sloan-Kettering Cancer Center
New York, NY
2006-

Member, Radioactive Drug Research Committee (RDRC)
New York Presbyterian Hospital/Weill-Cornell Medical Center
New York, NY
2007-

Member, Medical Internal Radionuclide Dosimetry (MIRD) Committee
Society of Nuclear Medicine
2008-

Guest Editor, *Seminars in Nuclear Medicine*
2008

Member, Advisory Committee on Medical Uses of Isotopes (ACMUI), Nuclear Regulatory Commission (NRC)
2010-
Vice-Chairman, 2015-

Associate Editor, *British Journal of Radiology*
2012-

Associate Editor, *Physica Medica - European Journal of Medical Physics*
2013-

PROFESSIONAL MEMBERSHIPS

American Physical Society

Sigma Pi Sigma

Society of Nuclear Medicine

Greater New York Chapter of the Society of Nuclear Medicine

Radiopharmaceutical Council of the Society of Nuclear Medicine

New York Academy of Medicine

Advisory Committee Member and Secretary, Nuclear Medicine Section

Chairman, 2011-

HONORS AND AWARDS

Full-tuition scholarship - Cooper Union, School of Engineering and Science, New York, NY (1973-77)

Dean's List - Cooper Union, School of Engineering and Science, New York, NY (1973-77)

Sigma Pi Sigma (elected 1976)

National Science Foundation Undergraduate Summer Research Fellow (1976)

National Cancer Institute National Research Science Awardee (1979-82)

Frank Lappin Horsfall, Jr. Award, Sloan-Kettering Division, Graduate School of Medical Sciences, Cornell University, New York NY(1979)

"Best Paper From a Young Investigator (First Place)", Second International Symposium on Radiopharmacology, Chicago, IL (1981)

Certificate of Recognition for Academic Achievement, Memorial Sloan-Kettering Cancer Center, New York,NY, (1982)

Fellow, New York Academy of Medicine

Member, National Council on Radiation Protection and Measurement (NCRP)

G William Morgan Lectureship, Health Physics Society, July 2008

Lakshman Rao and Shanta Chervu Memorial Lectureship, Albert Einstein College of Medicine/Montefiore Medical Center, November 2008

Berson-Yalow Award, Greater New York Chapter, Society of Nuclear Medicine, october 2012

BIBLIOGRAPHY

I. Peer-Reviewed Publications

1. **Zanzonico PB**, Fernandes G, and Good RA. The differential sensitivity of T cell and B cell mitogenesis to in vitro zinc deficiency. *Cell Immunol* 60: 203-211, 1981.
2. Dunzendorfer U, Schmall B, Bigler RE, **Zanzonico PB**, Conti PS, Dahl JR, Kleinert E, and Whitmore W. Synthesis and body distribution of alpha-aminoisobutyric acid-1- ^{11}C in normal and prostate cancer bearing rats after chemotherapy. *Eur J Nucl Med* 6: 535-538, 1981.
3. Riley RJ, **Zanzonico PB**, Masterson ME, St Germain JM, and Laughlin JS. Evaluation of the response to xenon-133 and radiations by thermoluminescent dosimeters used during the accident at Three Mile Island. *Health Phys* 42: 329-334, 1982.
4. **Zanzonico PB**, Bigler RE, and Schmall B. Neuroleptic binding sites: Specific labeling in mice using ^{18}F -haloperidol, a potential tracer for positron tomography. *J Nucl Med* 24: 408-416, 1983.
5. Conti PS, Schmall B, Bigler RE, **Zanzonico PB**, Reiman RE, Dahl JR, Jacobsen JK, Lee R, and Winstead MB. Synthesis and purification of sodium C-11 benzoate for physiological and metabolic studies: Evaluation in a tumor-bearing dog. *Int J Nucl Med Biol* 11: 179-183, 1984.
6. Schmall B, Conti PS, Bigler RE, **Zanzonico PB**, Dahl JR, Sundoro-Wu BM, Jacobsen JK, and Lee R. Synthesis and quality assurance of ^{11}C -alpha-aminoisobutyric acid (AIB), a potential tracer for imaging and amino acid transport studies in normal and malignant tissues. *Int J Appl Rad Isotope* 11: 209-214, 1984.
7. Bigler RE, **Zanzonico PB**, Schmall B, Conti PS, Dahl JR, Rothman L, Sgouros G, and MacEwen EG. Evaluation of ^{11}C - alpha-isobutyric acid for tumor detection and amino acid transport measurement: Spontaneous canine tumor studies. *Eur J Nucl Med* 10: 48-55, 1985.
8. Welt S, Mattes MJ, Grando R, Thomson TM, Leonard RW, **Zanzonico PB**, Bigler RE, Yeh S, Oettgen L, and Old L. Monoclonal antibody localization to an intracellular antigen images human melanoma transplants in nu/nu mice. *Proc Natl Acad Sci* 84: 4200-4204, 1987.
9. Bigler RE and **Zanzonico PB**. The physics of radioimmunotherapy. *Am J Clin Oncol* 11: 199-202, 1988.
10. Schmall B, Conti PS, Bigler RE, **Zanzonico PB**, Reiman RE, Benua RS, Yeh SD, Dahl JR, Lee R, and Laughlin JS. Imaging studies of patients with malignant fibrous hystiocyoma using ^{11}C -alpha-aminoisobutyric acid (AIB). *Clin Nucl Med* 12: 22-26, 1987.

11. Hammer BE, Sacks W, Bigler RE, Hennessy MJ, Sacks S, Fleischer A, and **Zanzonico PB**. In vivo metabolism of [1-¹³C]glucose in monkey brain by ¹³C NMR spectroscopy. *Magnet Reson Med* 12: 1-5, 1990.
12. Sgouros G, Barest G, Thekkumthala J, Chui C, Mohan R, Bigler RE, and **Zanzonico PB**. Treatment planning for internal radionuclide therapy: Three-dimensional dosimetry for nonuniformly distributed radionuclides. *J Nucl Med* 31: 1884-1891, 1990.
13. Reich JB, Sierra J, Camp W, **Zanzonico P**, Deck MDF, and Plum F. Magnetic resonance imaging measurements and clinical changes accompanying transtentorial and foramen magnum brain herniation. *Ann Neurol* 33: 159-170, 1993.
14. Strand SE, **Zanzonico PB**, Johnson TK, Norrgren K, and Ingvar C. Pharmacokinetic modelling. *Med Phys* 20: 515-527 (Part 2), AAPM Report No 40, 1993.
15. Hardoof R, Braegelman F, **Zanzonico P**, Herrold EM, Lees RS, Lees AM, Dean RT, Lister-James J, and Boer JS. External imaging of atherosclerosis in rabbits using an ¹²³I-labeled synthetic peptide fragment. *J Clin Pharmacol* 33: 1039-1047, 1993.
16. Hardoff R, **Zanzonico P**, Braegelman F, Herrold EM, Lees RS, Lees AM, Dean RT, Lister-James J, and Borer JS. Localization of ^{99m}Tc-labeled ApoB synthetic peptide in arterial lesions of an experimental model of spontaneous atherosclerosis. *Am J Therapeut* 2: 88-99, 1995.
17. Khilnani N, Lee M, Winchester O, **Zanzonico P**, McCaffrey T, Trost D, Jagust M, Binkert B, and Sos T. In vitro model to evaluate the relative efficacy of catheter-directed thrombolytic strategies. *Acad Radiol* 3: 121-128, 1996.
18. Lu P, **Zanzonico P**, Lister-James J, Goldfine SM, Herrold E, Lees RS, Lees AM, Dean RT, Moyer BR, and Borer JS. Biodistribution and autoradiographic localization of I-125-labeled synthetic peptide in aortic atherosclerosis in cholesterol-fed rabbits. *Am J Therapeutics* 3: 673-680, 1996.
19. Zuckier LS, Stabin M, Krynckyi BR, **Zanzonico P**, and Binkert B. Effect of prior radiopharmaceutical administration on Schilling test performance: Analysis and recommendations. *J Nucl Med* 37: 1995-1999, 1996.
20. The Einstein/Cornell Collaborative Hypertension Group-Blaufox MD, Fine EJ, Heller S, Hurkey J, Jagust M, Li Y, Mann SJ, Pickering TG, **Zanzonico P**, and Zhang CG. Propective study of simultaneous orthiodohippurate and diethylenetriaminepentaacetic acid captopril renography. *J Nucl Med* 39: 522-528, 1998.
21. Khilnani NM, Winchester PA, **Zanzonico P**, Trost BW, Binkert B, and Sos TA. In vitro evaluation of the relative thrombolytic efficiency of forced intrathrombotic injections: Saline versus urokinase. *J Vasc Interv Radiol* 9: 786-792, 1998.

22. Mack CA, Magovern, CJ, Budenbender KT, Patel SR, Schwarz EA, **Zanzonico P**, Ferris B, Sanborn T, Isom OW, Crystal RG and Rosengart TK. Salvage angiogenesis induced by adenoviral-mediated gene transfer of vascular endothelial growth factor protects against threatened ischemic vascular occlusion. *J Vasc Surg* 27: 699-709, 1997.
25. Mack CA, Patel SR, Schwarz EA, **Zanzonico P**, Hahn RT, Ilercil A, Devereux RB, Goldsmith SJ, Christian TF, Sanborn TA, Kovesdi I, Hackett N, Isom W, Crystal RG and Rosengart TK. Biological bypass utilizing adenovirus-mediated gene transfer of the cDNA for vascular endothelial growth factor121 improves myocardial perfusion and function in the ischemic porcine heart. *J Thorac Cardiovasc Surg* 115: 168-176, 1998.
26. Blaufox MD, Fine EJ, Heller S, Hurley J, Jagust M, Li Y, Mann SJ, Pickering TG, P **Zanzonico P**, and Zhang CG. The Einstein/Cornell Collaborative Hypertension Group. Prospective study of simultaneous orthoiodohippurate and diethylenetriaminepentaacetic acid captopril renography.. *J Nucl Med* 39: 522-528, 1998.
27. **Zanzonico P**, Binkert B, and Goldsmith SJ. Release criteria for patients treated with pure β -ray emitters based on the calculated *bremsstrahlung* hazard. *J Nucl Med* 40: 1024-1028, 1999.
24. Rini JN, Vallabhajosula S, **Zanzonico P**, Hurley JR, Becker DV, and Goldsmith SJ. Thyroid uptake of liquid versus capsule ^{131}I tracers in hyperthyroid patients treated with liquid ^{131}I . *Thyroid* 9: 347-352, 1999.
28. **Zanzonico P**. Age-dependent thyroid absorbed doses for radiobiologically significant radioisotopes of iodine. *Health Phys* 78: 60-67, 2000.
29. Lee LY, Patel SR, Hackett NR, Mack CA, Polce DR, El-Sawy T, Hachamovitch R, **Zanzonico P**, Sanborn TA, Parikh M, Isom OW, Crystal RG. Rosengart TK. Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. *Ann Thorac Surg* 69: 14-23, 2000.
30. **Zanzonico P**, Siegel J, and St Germain J. A generalized algorithm for determining the time of release and the duration of post-release radiation precautions following radionuclide therapy. *Health Phys* 6: 648-659, 2000.
31. **Zanzonico P** and Becker DV. Effects of time of administration and dietary iodine levels on potassium iodide (KI) blockade of thyroid irradiation by ^{131}I from radioactive fallout. *Health Phys* 78: 660-667, 2000.
32. Ugur O, Kathari PJ, **Zanzonico P**, Ruan S, Guenther I, Maecke HR, Finn RD, and Larson SM. Ga-66 Labeled Somatostatin Analogue DOTA-DPhe¹-Tyr³-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. *Nucl Med Biol* 29: 147-157, 2002.
33. Urano M, Chen Y, Humm J, Koutcher JA, **Zanzonico P**, and Ling C. Measurement of tumor tissue oxygen tension using a time-resolved luminescence-based optical OxyLite probe: Comparison with a paired survival assay. *Radiation Res* 158: 167-173, 2002.

34. Koehne G, Doubrovin M, Doubrovina E, **Zanzonico P**, Gallardo HF, Ivanova A, Balatoni J, Teruya-Feldstein J, Heller G, May C, Ponomarev V, Ruan S, Finn R, Blasberg RG, Bornmann W, Riviere I, Sadelain M, O'Reilly RJ, Larson SM, Gelovani Tjuvajev JG. *In vivo* scintigraphic imaging of human hsv-tk transduced tumor antigen-specific T lymphocytes. *Nature Biotechnology* 21: 405-413, 2003.
35. Palm S, Enmon Jr RM, Matei SB, Kolbert KS, Xu S, Pellegrini V, **Zanzonico PB**, Finn RL, Koutche JA, Larson SM and Sgouro G. Pharmacokinetics and Biodistribution of ⁸⁶Y-Herceptin for ⁹⁰Y dosimetry in an ovarian carcinoma model: Correlative microPET and MR imaging. *J Nucl Med* 44: 1148-1155, 2003.
36. Humm JL, Ballon D, Hu J, Ruan S, Chui C, Tulipano PK, Erdi A, Koutcher J, Zakian K, Urano M, **Zanzonico P**, Mattis C, Dyke J, Chen Y, Harrington P, O'Donoghue JA and C. Ling C. A stereotactic method for the three-dimensional registration of multi-modality biologic images in animals: NMR, PET, histology, and autoradiograph. *Med Physics* 30: 2303-2314, 2003.
37. **Zanzonico P**, Chapman JD, Schneider R, Cai S, Larson S, Chen Y, Finn R, Ruan S, Humm J, Ling C. I124-Iodo-azomycin-galactoside (IAZG) imaging of tumor hypoxia in mice with serial microPET™ scanning, *Eur J Nucl Med Mol Imaging* 31: 117-128, 2004.
38. Cheung NK, Modak S, Lin Y, Guo H, **Zanzonico P**, Chung J, Zuo Y, Sanderson J, Wilbert S, Theodore LJ, Axworthy DB, Larson SM. Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2. *J Nucl Med.* 45:867-877, 2004.
39. Wen B, Burgman P, **Zanzonico P**, O'Donoghue J, Cai S, Finn R, Serganova I, Blasberg R, Gelovani J, Li G, and Ling C. A preclinical model for noninvasive imaging of hypoxia-induced gene expression; comparison with an exogenous marker of tumor hypoxia. *Eur J Nucl Med Mol Imaging* 31: 1530-1538, 2004.
40. **Zanzonico PB**, Finn R, Pentlow KS, Erdi Y, Beattie B, Akhurst T, Squire O, Morris M, Scher H, McCarthy T, Welch M, Larson SM, Humm JL. PET-based radiation dosimetry in man of ¹⁸F-fluoro-dihydrotestosterone (FDHT), a new radiotracer for imaging prostate cancer. *J Nucl Med* 45: 1966-71, 2004.
41. **Zanzonico PB**, Becker DV, and Hurley JR. Enhancement of radioiodine treatment of "small pool" hyperthyroidism using antithyroid drugs: Kinetics and dosimetry, *J Nucl Med* 45: 2102-08, 2004.
42. O'Donoghue JA, **Zanzonico P**, Pugachev A, Wen B, Smith-Jones P, Cai S, Burnazi E, Finn RD, Burgman P, Ruan S, Lewis JS, Welch MJ, Ling CC, Humm JL. Assessment of regional tumor hypoxia using ¹⁸F-fluoromisonidazole and ⁶⁴Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, pO₂ probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. *Int J Radiat Oncol Biol Phys* 61:1493-502, 2005.
43. Che J, Doubrovin M, Serganova I, Ageyeva L, **Zanzonico P**, and Blasberg R. hNIS-IRES-eGFP dual reporter gene imaging. *Mol Imaging* 4: 128-36, 2005.

44. Miller RW and **Zanzonico PB**. Radioiodine fallout and breast-feeding. *Rad Res* 169: 140-149, 2005.
45. Forster GJ, Santos EB, Smith-Jones PM, **Zanzonico P**, and Larson SM. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled dota-biotin: strategies for reduction of the renal dose. *J Nucl Med* 47: 140-149, 2006.
46. **Zanzonico P**, Campa J, Polycarpe-Holman D, Forster G, Finn R, Larson S, Humm J, and Ling C. Animal-specific positioning molds for registration of repeat imaging studies: Comparative microPET™ imaging of F18-labeled fluoro-deoxyglucose and fluoro-misonidazole in rodent tumors. *Nucl Med Biol* 33: 65-70, 2006.
47. **Zanzonico P**, Rothenberg HW, and Strauss HW. Radiation exposure of computed tomography and direct intracoronary angiography: Risk has its reward. *J Am Coll Cardiol* 47: 1846-1849, 2006.
48. Li XF, **Zanzonico P**, Ling CC, and O'Donoghue J. Visualization of experimental lung and bone metastases in live nude mice by X-ray micro-computed tomography. *Technol Cancer Res Treat* 5: 147-55, 2006.
49. **Zanzonico P**, Koehne G, Gallardo HF, Doubrovin M, Doubrovina E, Finn R, Blasberg RG, Riviere I, O'Reilly RJ, Sadelain M, Larson S. [¹³¹I]-FIAU labeling of genetically transduced, tumor-teactive lymphocytes: Cell-level dosimetry and dose-dependent toxicity. *Eur J Nucl Med Molec Imaging* 33: 988-97, 2006.
50. Tseng JC, **Zanzonico PB**, Levin B, Finn R, Larson SM, Meruelo D. Tumor-specific in vivo transfection with HSV-1 thymidine kinase gene using a Sindbis viral vector as a basis for prodrug ganciclovir activation and PET. *J Nucl Med* 47: 1136-43, 2006.
51. Pandit-Taskar N, Dauer LT, Montgomery L, St Germain J, **Zanzonico PB**, Divgi CR. Organ and fetal absorbed dose estimates from 99mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients. *J Nucl Me* 47: 1202-8, 2006.
52. McBride WJ, **Zanzonico P**, Sharkey RM, Noren C, Karacay H, Rossi EA, Losman MJ, Brard PY, Chang CH, Larson SM, Goldenberg DM. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide. *J Nucl Med* 47:1678-88, 2006.
53. Bradbury MS, Panagiotakos G, Chan BK, Tomishima M, Zanzonico P, Vider J, Ponomarev V, Studer L, Tabar V. Optical bioluminescence imaging of human ES cell progeny in the rodent CNS. *J Neurochem* 10: 2029-39, 2007.
54. Dauer LT, St Germain J, Williamson MJ, **Zanzonico P**, Modak S, Cheung NK, and Divgi C. Whole-body clearance kinetics and external dosimetry of ¹³¹I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma. *Health Phys* 92: 33-39, 2007.
55. Beattie BJ, Forster GJ, Govantes R, Le CH, Longo VA, **Zanzonico PB**, Bidaut L, Blasberg RG, Koutcher JA. Multimodality registration without a dedicated multimodality scanner. *Mol Imaging* 6: 108-20, 2007.
56. Tulipano K, Tao Y, Millar WS, **Zanzonico P**, Kolbert K, Xu H, Chen L, Yu H, Lussie YA, and Friedman C. Natural language processing and visualization in the molecular imaging domain. *J Biomed Informatics* 40: 270-281. 2007.

57. Moroz MA, Serganova I, **Zanzonico P**, Ageyeva L, Beresten T, Dyomina E, Burnazi E, Finn RD, Blasberg RG. Imaging hNET reporter gene expression with [124I]-MIBG. *J Nucl Med* 48: 827-836, 2007.
58. McDevitt MR, Chattopadhyay D, Jaggi JS, Finn RD, **Zanzonico PB**, Villa C, Rey D, Mendenhall J, Batt CA, Njardarson JT, and Scheinberg DA PET imaging of soluble yttrium-86-labeled carbon nanotubes in mice. *PLoS ONE* 2 (e907): 1-10, 2007.
59. Jaggi JS, Carrasquillo JA, Seshan SV, **Zanzonico P**, Henke E, Nagel A, Schwartz J, Beattie B, Kappel BJ, Chattopadhyay D, Xiao J, Sgouros G, Larson SM, Scheinberg DA. Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor. *J Clin Invest* 117:2422-2430, 2007.
60. Bernal P, Raoul JL, Vidmar G, Seregotov E, Sundram FX, Kumar A, Jeong JM, Pusuwan P, Divgi C, **Zanzonico P**, Stare J, Buscombe J, Thi Minh CT, Saw MM, Chen S, Ogbac R, Padhy AK. Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multinational study. *Int J Radiat Oncol Biol Phys* 69: 1448-55, 2007.
61. Kramer K, Humm JL, Souweidane MM, **Zanzonico PB**, Dunkel, IJ, Gerald WL, Khakoo Y, Yeh SD, Yeung HW, Finn RD, Wolden SL, Larson SM, and Cheung NK. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131I-3F8. *J Clin Oncol* 25: 465-70, 2007.
62. Doubrovina MM, Doubrovina ES, **Zanzonico PB**, Sadelain M, Larson SM, and O'Reilly RJ. In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene. *Cancer Res* 67: 11959-69, 2007.
63. Brader P, Riedl CC, Woo Y, Ponomarev V, **Zanzonico P**, Wen B, Cai S, Hricak H, Fong Y, Blasberg R, and Serganova I. Imaging of hypoxia-driven gene expression in an orthotopic liver tumor model. *Mol Cancer Ther* 6: 2900-8, 2007.
64. Zhang M, Chen Q, Li X, O'Donoghue J, Ruan S, **Zanzonico P**, Ling C, Humm J. Image deconvolution in autoradiography: A preliminary study. *Med Phys* 24: 2363-, 2007.
65. Lee NY, Mechalakos JG, Nehmeh SA, Lin Z, Grecco C, **Zanzonico PB**, Chan K, Squire O, Cai S, Ling CC, Humm JL and Schöder H. Fluorine-18-labeled fluoro-misonidazole positron emission and computed tomography guided intensity-modulated radiation therapy in the treatment of head and neck cancer. *Int J Radiat Onc Biol Phys* 70: 2-13, 2008.
66. Riedl CC, Brader P, **Zanzonico P**, Reed V, Singh P, Humm J, Hricak, H, Fong Y, and Ling C. Tumor hypoxia imaging in orthotopic liver tumors and peritoneal metastasis: Comparative study featuring dynamic 18F-MISO and 124I-IAZG PET in the same study cohort. *Eur J Nucl Med Mol Imaging* 35: 39-46, 2008.
67. Nehmeh SA, Schöder H, Lee, NY Squire O, **Zanzonico PB**, Erdi YE, Grecco C, Larson SM, Ling CC and Humm JL. Reproducibility of ¹⁸F-MISO distribution in head and neck cancer. *Int J Radiat Onc Biol Phys* 70: 235-42, 2008.

68. Riedl CC, Brader P, **Zanzonico PB**, Chun YS, Woo Y, Singh P, Carlin S, Wen B, Ling CC, Hricak H, and Fong Y. Imaging hypoxia in orthotopic rat liver tumors with iodine 124-labeled iodoazomycin galactopyranoside PET. *Radiology*. 248: 561-70, 2008.
69. Bradbury MS, Hambardzumyan D, **Zanzonico PB**, Schwartz J, Cai S, Burnazi EM, Longo V, Larson SM, and Holland EC. Dynamic microPETTM imaging of tumor proliferation using ¹⁸F-FLT in a genetically engineered mouse model of high grade glioma. *J Nucl Med* 49: 422-429, 2008.
70. Brader P, Stritzker J, Riedl CC, **Zanzonico P**, Cai S, Burnazi EM, Ghani ER, Hricak H, Szalay AA², Fong Y, and Blasberg R. *E coli* Nissle 1917 facilitates tumor detection by PET and optical imaging. *Clin Cancer Res* 14:2295-302, 2008.
71. Zhang M, Huang M, Le C, **Zanzonico P**, Claus F, Kolbert K, Martin K, Ling C, Koutcher JA, and Humm J. Accuracy and reproducibility of tumor positioning during prolonged and multi-modality animal imaging studies. *Phys Med Biol* 53: 5867-82, 2008.
72. Zhang M, Chen Q, Li XF, O'Donoghue J, Ruan S, **Zanzonico P**, Ling CC, and Humm JL. Image deconvolution in digital autoradiography: a preliminary study *Med Phys* 35:522-30, 2008.
73. **Zanzonico PB**, Dauer LT, and St Germain J, Operational radiation safety for PET/CT, SPECT/CT, and cyclotron facilities. *Health Phys* 95: 554-570.
74. **Zanzonico P**. Routine quality control of Nuclear Medicine instrumentation: A brief review. *J Nucl Med* 49: 1114-31, 2008.
75. DiResta GR, Manoso MW, Naqvi A, **Zanzonico P**, Smith-Jones P, Tyler W, Morris C, Healey JH. Bisphosphonate Delivery to Tubular Bone Allografts. *Clin. Ortho. Related Res* 466: 1871-9, 2008.
76. He F, Deng X, Wen B, Liu Y, Sun X, Xing L, Minami A, Huang Y, Chen Q, **Zanzonico PB**, Ling CC, Li GC. Noninvasive molecular imaging of hypoxia in human xenografts: comparing hypoxia-induced gene expression with endogenous and exogenous hypoxia markers. *Cancer Res* 15: 8597-606, 2008.
77. Cormode DP, Skajaa T, van Schooneveld MM, Koole R, Jarzyna P, Lobatto ME, Calcagno C, Barazza A, Gordon RE, **Zanzonico P**, Fisher EA, Fayad ZA, Mulder WJ. Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. *Nano Lett* 8: 3715-23, 2008.
78. Cho HJ, Ackerstaff E, Carlin S, Lupu ME, Wang Y, Rizwan A, O'Donoghue J, Ling CC, Humm JL, **Zanzonico PB**, and Koutcher JA. Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic MRI and PET studies of a preclinical tumor model of tumor hypoxia. *Neoplasia* 11: 247-59, 2009.

79. Chen X, Mitsutake N, LaPerle K, Akenob N, **Zanzonico P**, Longo VA, Mitsutake S, Kimura ET, Geiger H, Santos E, Wendel HG, Francoa A, Knaufa JA, and Fagin JA. Endogenous expression of HrasG12V induces developmental defects and neoplasms with copy number imbalances of the oncogene. *Proc Natl Academy Sciences* 106: 7979-84, 2009.
80. Wang W, Georgi JC, Nehmeh SA, Narayanan M, Paulus T, Bal M, O'Donoghue J, **Zanzonico PB**, Schmidtlein CR, Lee NY, and Humm JL. Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging. *Phys Med Biol* 54: 3083-99, 2009.
81. Brader P, Kelly KJ, Chen N, Yu YA, Zhang Q, **Zanzonico P**, Burnazi EM, Ghani RE, Serganova I, Hricak H, Szalay AA, Fong Y, and Blasberg RG. Imaging a genetically engineered oncolytic Vaccinia virus (GLV-1h99) using a human norepinephrine transporter reporter gene. *Clin Cancer Res* 15: 3791-3801, 2009.
82. Chang J, Wen B, Kazanzides P, **Zanzonico P**, Finn RD, Fichtinger G, and Ling CC. A robotic system for ¹⁸F-FMISO PET-guided intratumoral pO₂ measurements. *Med Phys* 36: 5301-9, 2009.
83. Ruggiero A, Brader P, Serganova I, **Zanzonico P**, Cai S, Lipman NS, Hricak H, and Blasberg RG. Different strategies for reducing intestinal background radioactivity associated with imaging HSV1-tk expression using established radionucleoside probes. *Mol Imaging* 9: 47-58, 2010.
84. Beattie BJ, Smith-Jones PM, Jhanwar YS, Schöder H, Schmidtlein CR, Morris MJ, **Zanzonico P**, Squire O, Meirelles GS, Finn R, Namavari M, Cai S, Scher HI, Larson SM, and Humm JL. Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. *J Nucl Med* 51: 183-92, 2010.
85. Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, Brill AB, Song H, Howell RW, Akabani G; SNM MIRD Committee, Bolch WE, Brill AB, Fisher DR, Howell RW, Meredith RF, Sgouros G, Wessels BW, and **Zanzonico PB**. MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. *J Nucl Med* 51: 311-28, 2010.
86. Kramer K, Kushner BH, Modak S, Pandit-Taskar N, Smith-Jones P, **Zanzonico P**, Humm JL, Xu H, Wolden SL, Souweidane MM, Larson SM, and Cheung NK. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. *Neurooncol* 97: 409-18, 2010.
87. Sofou S, Enmon R, Palm S, Kappel B, **Zanzonico P**, McDevitt MR, Scheinberg DA, and Sgouros G. Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer. *J Liposome Res* 20: 330-340, 2010.

88. He P, Kramer K, Smith-Jones P, **Zanzonico P**, Humm J, Larson SM, Cheung NK. Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid. *Eur J Nucl Med Mol Imaging* 38: 334-42, 2011.
89. Medina OP, Pillarsetty N, Glekas A, Punzalan B, Longo V, Gönen M, **Zanzonico P**, Smith-Jones P, Larson SM. Optimizing tumor targeting of the lipophilic EGFR-binding radiotracer SKI 243 using a liposomal nanoparticle delivery system. *J Control Release* 149: 292-296, 2011.
90. Oehler C, O'Donoghue JA, Russell J, **Zanzonico P**, Lorenzen S, Ling CC, Carlin S. ¹⁸F-Fluoromisonidazole PET Imaging as a Biomarker for the Response to 5,6-Dimethylxanthenone-4-Acetic Acid in Colorectal Xenograft Tumors. *J Nucl Med* 52: 437-44, 2011.
91. Balter S, **Zanzonico P**, Reiss GR, Moses JW. Radiation is not the only risk. *Am J Roentgenol.* 196: 762-7, 2011.
92. Haddad D, Chen NG, Zhang Q, Chen CH, Yu YA, Gonzalez L, Carpenter SG, Carson J, Au J, Mitra A, Gonen M, **Zanzonico PB**, Fong Y, Szalay AA. Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus. *J Transl Med* 9: 36, 2011 .
93. Benezra M, Penate-Medina O, **Zanzonico PB**, Schaer D, Ow H, Burns A, Destanchina E, Longo V, Herz E, Iyer S, Wolchok J, Larson SM, Wiesner U, Bradbury MS. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. *J Clin Invest* 121: 2768-2780, 2011 .
94. Gholami S, Haddad D, Chen CH, Chen NG, Zhang Q, **Zanzonico PB**, Szalay AA, Fong Y. Novel therapy for anaplastic thyroid carcinoma cells using an oncolytic vaccinia virus carrying the human sodium iodide symporter. *Surgery* 150: 1040-1047, 2011.
95. Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, Bollag G, Kolesnick R, Thin TH, Rosen N, **Zanzonico P**, Larson SM, Refetoff S, Ghossein R, Fagin JA. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. *J Clin Invest* 121: 4700-4711, 2011.
96. Dauer LT, **Zanzonico P**, Tuttle RM, Quinn DM, Strauss HW. The Japanese tsunami and resulting nuclear emergency at the Fukushima Daiichi power facility: technical, radiologic, and response perspectives. *J Nucl Med* 52: 1423-1432, 2011.
97. Carrasquillo JA, Pandit-Taskar N, O'Donoghue JA, Humm JL, **Zanzonico P**, Smith-Jones PM, Divgi CR, Pryma DA, Ruan S, Kemeny NE, Fong Y, Wong D, Jaggi JS, Scheinberg DA, Gonen M, Panageas KS, Ritter G, Jungbluth AA, Old LJ, Larson SM. (124)I-huA33 antibody PET of colorectal cancer. *J Nucl Med* 52: 1173-1180, 2011.

98. Dunphy MP, **Zanzonico P**, Veach D, Somwar R, Pillarsetty N, Lewis J, Larson S. Dosimetry of ^{18}F -labeled tyrosine kinase inhibitor SKI-249380, a dasatinib-tracer for PET imaging. *Mol Imaging Biol* 14: 25-31, 2012.
99. Stelter L, Evans MJ, Jungbluth AA, **Zanzonico P**, Ritter G, Ku T, Rosenfeld E, Bomalaski JS, Old L, Larson SM. Novel mechanistic insights into arginine deiminase pharmacology suggest ^{18}F -FDG is not suitable to evaluate clinical response in melanoma. *J Nucl Med* 53: 281-286, 2012.
100. Dewaraja YK, Frey EC, Sgouros G, Brill AB, Roberson P, **Zanzonico PB**, Ljungberg M. MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. *J Nucl Med* 53: 1310-1325, 2012.
101. Thorek DL, Abou DS, Beattie BJ, Bartlett RM, Huang R, **Zanzonico PB**, Grimm J. Positron lymphography: Multimodal, high-resolution, dynamic mapping and resection of lymph nodes after intradermal injection of ^{18}F -FDG. *J Nucl Med* 53: 1438-1445, 2012.
102. Haddad D, Chen CH, Carlin S, Silberhumer G, Chen NG, Zhang Q, Longo V, Carpenter SG, Mitra A, Carson J, Au J, Gonen M, **Zanzonico PB**, Szalay AA, Fong Y. Imaging characteristics, tissue distribution, and spread of a novel oncolytic vaccinia virus carrying the human sodium iodide symporter. *PLoS One* 7: e41647, 2012.
103. Bartlett RM, Beattie BJ, Naryanan M, Georgi JC, Chen Q, Carlin SD, Roble G, **Zanzonico PB**, Gonen M, O'Donoghue J, Fischer A, Humm JL. Image-guided pO_2 probe measurements correlated with parametric images derived from ^{18}F -Fluoromisonidazole Small-Animal PET data in rats. *J Nucl Med* 53: 1608-1615, 2012.
104. Benezra M, Hambarzumyan D, Penate-Medina O, Veach DR, Pillarsetty N, Smith-Jones P, Phillips E, Ozawa T, **Zanzonico PB**, Longo V, Holland EC, Larson SM, Bradbury MS. Fluorine-labeled dasatinib nanoformulations as targeted molecular imaging probes in a PDGFB-driven murine glioblastoma model. *Neoplasia* 14: 1132-1143, 2012.
105. Stelter L, Tseng JC, Torosjan A, Levin B, Longo VA, Pillarsetty N, **Zanzonico P**, Meruelo D, Larson SM. Tumor-specific targeting with modified Sindbis viral vectors: evaluation with optical imaging and positron emission tomography in vivo. *Mol Imaging Biol* 2012. In press.
106. Stoyanova R, Huang K, Sandler K, Cho H, Carlin S, **Zanzonico PB**, Koutcher JA, Ackerstaff E. Mapping Tumor Hypoxia In Vivo Using Pattern Recognition of Dynamic Contrast-enhanced MRI Data. *Transl Oncol* 5: 437-447, 2012.
107. Stelter L, Evans MJ, Jungbluth AA, Longo VA, **Zanzonico P**, Ritter G, Bomalaski JS, Old L, Larson SM. Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma. *Mol Imaging* 12: 67-73, 2013.

108. Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, **Zanzonico PB**, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Domínguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. *N Engl J Med* 368: 623-632, 2013.
109. Glick AF, Song YS, Brian Hwang B, John Lillvis J, **Zanzonico P**, Fuchs C, Roger N Pearse RN, Szabo P, and Weksler ME. Age matters: Young T lymphocytes offer better protection from myeloma proliferation. *Immunity & Ageing* 10: 5, 2013.
110. Au JT, Craig G, Longo V, **Zanzonico P**, Mason M, Fong Y, Allen PJ. Gold nanoparticles provide bright long-lasting vascular contrast for CT imaging. *Am J Roentgenol* 10: 1347-51, 2013.
111. Zeglis BM, Sevak KK, Reiner T, Mohindra P, Carlin SD, **Zanzonico P**, Weissleder R, Lewis JS. A pretargeted pet imaging strategy based on bioorthogonal diels-alder click chemistry. *J Nucl Med* 54: 1389-96, 2013.
112. O'Donoghue JA Guillem JG, Schoeder H, Lee NY, Divgi CR, Ruby JA, Humm JL, Lee-Kong SA, Burnazi EM, Cai S, Carlin SD, Leibold T, **Zanzonico PB**, Ling CC. Pilot study of PET imaging of ¹²⁴I-Iodo-azomycin Galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer. *EJNMMI Research* 3: 1-10, 2013.
113. Xing L, Sun X, Deng X, Kotedia K, **Zanzonico PB**, Ackerstaff E, Koutcher JA, Ling CC, Li GC. A triple suicide gene strategy that improves therapeutic effects and incorporates multimodality molecular imaging for monitoring gene functions. *Cancer Gene Ther* 20: 358-365, 2013.
114. Belin LJ, Ady JW, Lewis C, Marano D, Gholami S, Mojica K, Eveno C, Longo V, **Zanzonico PB**, Chen NG, Szalay AA, Fong Y. An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesothelioma. *Surgery* 154: 486-95, 2013.
115. Emmetiere F, Irwin C, Viola-Villegas NT, Longo V, Cheal SM, **Zanzonico P**, Pillarsetty N, Weber WA, Lewis JS, Reiner T. ¹⁸F-labeled-bioorthogonal liposomes for in vivo targeting. *Bioconjug Chem* 24: 1784-9, 2013.
116. Dewaraja YK, Ljungberg M, Green AJ, **Zanzonico PB**, Frey EC. MIRD pamphlet No. 24: Guidelines for quantitative ¹³¹I SPECT in dosimetry applications. *J Nucl Med* 54: 2182-8, 2013.
117. Gholami S, Marano A, Chen NG, Aguilar RJ, Frentzen A, Chen CH, Lou E, Fujisawa S, Eveno C, Belin L, **Zanzonico P**, Szalay A, Fong Y. A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer. *Breast Cancer Res Treat.* 148: 489-99, 2014.

118. Phillips E, Penate-Medina O, **Zanzonico** PB, Carvajal RD, Mohan P, Ye Y, Humm J, Gönen M, Kalaigian H, Schöder H, Strauss HW, Larson SM, Wiesner U, Bradbury MS. Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. *Sci Transl Med.* 6: 260, 2014.
119. Cheal SM, Xu H, Guo HF, **Zanzonico** PB, Larson SM, Cheung NK. Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex. *Mol Cancer Ther.* 2014 13: 803-12, 2014.
120. Cheal SM, Punzalan B, Doran MG, Evans MJ, Osborne JR, Lewis JS, **Zanzonico** P, Larson SM. Pairwise comparison of ^{89}Zr - and ^{124}I -labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma. *Eur J Nucl Med Mol Imaging* 41: 985-94, 2014.
121. Zhang H, Huang R, Cheung NK, Guo H, **Zanzonico** PB, Thaler HT, Lewis JS, Blasberg RG. Imaging the norepinephrine transporter in neuroblastoma: a comparison of ^{18}F -MFBG and ^{123}I -MIBG. *Clin Cancer Res.* 20: 2182-91, 2014.
122. Luther N, Zhou Z, **Zanzonico** P, Cheung NK, Humm J, Edgar MA, Souweidane MM. The potential of theragnostic ^{124}I -8H9 convection-enhanced delivery in diffuse intrinsic pontine glioma. *Neuro Oncol* 16: 800-6, 2014.
123. Jun KH, Gholami S, Song TJ, Au J, Haddad D, Carson J, Chen CH, Mojica K, **Zanzonico** P, Chen NG, Zhang Q, Szalay A, Fong Y. A novel oncolytic viral therapy and imaging technique for gastric cancer using a genetically engineered vaccinia virus carrying the human sodium iodide symporter. *J Exp Clin Cancer Res* 33: 2, 2014.
124. Cheal SM, Yoo B, Boughdad S, Punzalan B, Yang G, Dilhas A, Torchon G, Pu J, Axworthy DB, **Zanzonico** P, Ouerfelli O, Larson SM. Evaluation of glycodendron and synthetically modified dextran clearing agents for multistep targeting of radioisotopes for molecular imaging and radioimmunotherapy. *Mol Pharm* 11: 400-16, 2014.
125. Lohrmann C, Zhang H, Thorek DL, Desai P, **Zanzonico** PB, O'Donoghue J, Irwin CP, Reiner T, Grimm J, Weber WA. Cerenkov luminescence imaging for radiation dose calculation of a ^{90}Y -labeled gastrin-releasing peptide receptor antagonist. *J Nucl Med.* 56: 805-11, 2015.
126. Gholami S, Chen CH, Lou E, Belin LJ, Fujisawa S, Longo VA, Chen NG, Gönen M, **Zanzonico** PB, Szalay AA, Fong Y. Vaccinia virus GLV-1h153 in combination with ^{131}I shows increased efficiency in treating triple-negative breast cancer. *FASEB J* 28: 676-82, 2014.

127. Venneti S, Dunphy MP, Zhang H, Pitter KL, **Zanzonico** P, Campos C, Carlin SD, La Rocca G, Lyashchenko S, Ploessl K, Rohle D, Omuro AM, Cross JR, Brennan CW, Weber WA, Holland EC, Mellinghoff IK, Kung HF, Lewis JS, Thompson CB. Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. *Sci Transl Med* 11: 274, 2015.
128. Eveno C, Mojica K, Ady JW, Thorek DL, Longo V, Belin LJ, Gholami S, Johnsen C, **Zanzonico** P, Chen N, Yu T, Szalay AA, Fong Y. Gene therapy using therapeutic and diagnostic recombinant oncolytic vaccinia virus GLV-1h153 for management of colorectal peritoneal carcinomatosis. *Surgery* 15: 331-7, 2015.
129. **Zanzonico** P, Carrasquillo JA, Pandit-Taskar N, O'Donoghue JA, Humm JL, Smith-Jones P, Ruan S, Divgi C, Scott AM, Kemeny NE, Fong Y, Wong D, Scheinberg D, Ritter G, Jungbluth A, Old LJ, Larson SM. PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer. *Eur J Nucl Med Mol Imaging* 42: 1700-6, 2015. PMID: 26194713.
130. Gholami S, Chen CH, Belin LJ, Lou E, Fujisawa S, Antonacci C, Carew A, Chen NG, De Brot M, **Zanzonico** PB, Szalay AA, Fong Y. Vaccinia virus GLV-1h153 is a novel agent for detection and effective local control of positive surgical margins for breast cancer. *Breast Cancer Res* 2014. [Epub ahead of print]
131. Stelter L, Fuchs S, Jungbluth AA, Ritter G, Longo VA, **Zanzonico** P, Raschok N, Sauer IM, Bomalaski JS, Larson SM. Evaluation of arginine deiminase treatment in melanoma xenografts using ¹⁸F-FLT PET. *Mol Imaging Biol*. 2013 May 31. [Epub ahead of print]
132. Benezra M, Phillips E, Overholtzer M, **Zanzonico** PB, Tuominen E, Wiesner U, Bradbury MS. Ultrasmall integrin-targeted silica nanoparticles modulate signaling events and cellular processes in a concentration-dependent manner. *Small* 11: 1721-32, 2015.
133. Jeong J, Chen Q, Febo R, Yang J, Pham H, Xiong JP, **Zanzonico** PB, Deasy JO, Humm JL, Mageras GS. Adaptation, commissioning, and evaluation of a 3d treatment planning system for high-resolution small-animal irradiation. *Technol Cancer Res Treat*, 2015.
134. Kramer K, Pandit-Taskar N, **Zanzonico** P, Wolden SL, Humm JL, DeSelm C, Souweidane MM, Lewis JS, Cheung NK. Low incidence of radionecrosis in children treated with conventional radiation therapy and intrathecal radioimmunotherapy. *J Neurooncol* 123: 245-9, 2015.
135. Thorek DL, Kramer RM, Chen Q, Jeong J, Lupu ME, Lee AM, Moynahan ME, Lowery M, Ulmert D, **Zanzonico** P, Deasy JO, Humm JL, Russell J. Reverse-contrast imaging and targeted radiation therapy of advanced pancreatic cancer models. *Int J Radiat Oncol Biol Phys* 93; 444-53, 2015.

136. Melo DR, Brill AB, **Zanzonico P**, Vicini P, Moroz B, Kwon D, Lamart S, Brenner A, Bouville A, Simon SL. Organ dose estimates for hyperthyroid patients treated with ^{131}I : An update of the Thyrotoxicosis Follow-Up Study. *Radiat Res* 184: 595-610, 2015.
137. Cheal SM, Xu H, Guo HF, Lee SG, Punzalan B, Chalasani S, Fung EK, Jungbluth A, **Zanzonico PB**, Carrasquillo JA, O'Donoghue J, Smith-Jones PM, Wittrup KD, Cheung NK, Larson SM. Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ^{86}Y - or ^{177}Lu -DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates. *Eur J Nucl Med Mol Imaging* 43: 925-37, 2016.
138. Grkovski M, Schwartz J, Gönen M, Schöder H, Lee NY, Carlin SD, **Zanzonico PB**, Humm JL, Nehmeh SA. Feasibility of ^{18}F -fluoromisonidazole kinetic modeling in head and neck cancer using shortened acquisition times. *J Nucl Med* 57: 334-41, 2016.
139. Bradbury MS, Pauliah M, **Zanzonico P**, Wiesner U, Patel S. Intraoperative mapping of sentinel lymph node metastases using a clinically translated ultrasmall silica nanoparticle. *Nanomed Nanobiotechnol*, 2015.
140. Modak S, **Zanzonico P**, Carrasquillo JA, Kushner BH, Kramer K, Cheung NK, Larson SM, Pandit-Taskar N. Arsenic Trioxide as a radiation sensitizer for ^{131}I -metaiodobenzylguanidine therapy: results of a Phase II study. *J Nucl Med* 57: 231-7, 2016.
141. Fung EK, Cheal SM, Fareedy SB, Punzalan B, Beylergil V, Amir J, Chalasani S, Weber WA, Spratt DE, Veach DR, Bander NH, Larson SM, **Zanzonico PB**, Osborne JR. Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. *Eur J Nucl Med Mol Imaging Res* 6: 7. 2016.
142. Taldone T, Zatorska D, Ochiana SO, Smith-Jones P, Kozirowski J, Dunphy MP, **Zanzonico P**, Bolaender A, Lewis JS, Larson SM, Chiosis G, Pillarsetty NV. Radiosynthesis of the iodine-124 labeled HSP90 inhibitor PU-H71. *J Labelled Comp Radiopharm* 59: 129-32, 2016.
143. Rodina A, Wang T, Yan P, Gomes ED, Dunphy MP, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H, Caldas-Lopes E, Alpaugh M, Corben A, Riolo M, Beattie B, Pressl C, Peter RI, Xu C, Trondl R, Patel HJ, Shimizu F, Bolaender A, Yang C, Panchal P, Farooq MF, Kishinevsky S, Modi S, Lin O, Chu F, Patil S, Erdjument-Bromage H, **Zanzonico P**, Hudis C, Studer L, Roboz GJ, Cesarman E, Cerchiatti L, Levine R, Melnick A, Larson SM, Lewis JS, Guzman ML, Chiosis G. The epichaperome is an integrated chaperome network that facilitates tumour survival. *Nature* 538: 397-401, 2016.

144. Kim SE, Zhang L, Ma K, Riegman M, Chen F, Ingold I, Conrad M, Turker MZ, Gao M, Jiang X, Monette S, Pauliah M, Gonen M, **Zanzonico P**, Quinn T, Wiesner U, Bradbury MS, Overholtzer M. Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth. *Nat Nanotechnol.* 11: 977-985, 2016.
145. Grkovski M, Schwartz J, Rimner A, Schöder H, Carlin SD, **Zanzonico PB**, Humm JL, Nehmeh SA. Reproducibility of ^{18}F -fluoromisonidazole intratumour distribution in non-small cell lung cancer. *EJNMMI Res* 6: 79, 2016.
146. Houghton JL, Membreno R, Abdel-Atti D, Cunanan KM, Carlin S, Scholz WW, **Zanzonico PB**, Lewis JS, Zeglis BM. Establishment of the in vivo efficacy of pretargeted radioimmunotherapy utilizing inverse electron demand Diels-Alder click chemistry. *Mol Cancer Ther* 16: 124-133, 2017.
147. Cheal SM, Fung EK, Patel M, Xu H, Guo HF, **Zanzonico PB**, Monette S, Wittrup KD, Cheung NV, Larson SM. Curative multicycle radioimmunotherapy monitored by quantitative SPECT/CT-based theranostics, using bispecific antibody pretargeting strategy in colorectal cancer. *J Nucl Med* 58: 1735-1742, 2017.
148. Chen F, Ma K, Zhang L, Madajewski B, **Zanzonico P**, Sequeira S, Gonen M, Wiesner U, Bradbury MS. Target-or-Clear Zirconium-89 Labeled Silica Nanoparticles for Enhanced Cancer-Directed Uptake in Melanoma: A Comparison of Radiolabeling Strategies. *Chem Mater* 29: 8269-8281, 2017.
149. Chen F, Ma K, Benezra M, Zhang L, Cheal SM, Phillips E, Yoo B, Pauliah M, Overholtzer M, **Zanzonico P**, Sequeira S, Gonen M, Quinn T, Wiesner U, Bradbury MS. Cancer-Targeting Ultrasmall Silica Nanoparticles for Clinical Translation: Physicochemical Structure and Biological Property Correlations. *Chem Mater* 29: 8766-8779, 2017.
150. Nichols KJ, Robeson W, Yoshida-Hay M, **Zanzonico PB**, Leveque F, Bhargava KK, Tronco GG, Palestro CJ. Alternative means of estimating ^{131}I maximum permissible activity to treat thyroid cancer. *J Nucl Med* 58: 1588-1595, 2017.
151. Pandit-Taskar N, **Zanzonico P**, Hilden P, Ostrovnaya I, Carrasquillo JA, Modak S. Assessment of organ dosimetry for planning repeat treatments of high-dose ^{131}I -MIBG Therapy: ^{123}I -MIBG Versus Post-therapy ^{131}I -MIBG Imaging. *Clin Nucl Med* 42: 741-748, 2017.
152. Schwartz J, Grkovski M, Rimner A, Schoder H, **Zanzonico PB**, Carlin SD, Staton KD, Humm JL, Nehmeh SA. Pharmacokinetic analysis of dynamic ^{18}F -FMISO PET data in non-small cell lung cancer. *J Nucl Med* 58: 911-919, 2017.

153. O'Donoghue JA, Lewis JS, Pandit-Taskar N, Fleming SE, Schoder H, Larson SM, Beylertgil V, Ruan S, Lyashchenko SK, **Zanzonico PB**, Weber WA, Carrasquillo J, Janjigian YY. Pharmacokinetics, Biodistribution, and Radiation Dosimetry for ^{89}Zr -Trastuzumab in Patients with Esophagogastric Cancer. *J Nucl Med* 59:161-166, 2018.
154. Pandit-Taskar N, **Zanzonico P**, Staton KD, Carrasquillo JA, Reidy-Lagunes D, Lyashchenko S, Burnazi E, Zhang H, Lewis JS, Blasberg R, Larson SM, Weber WA, Modak S. Biodistribution and Dosimetry of ^{18}F -Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies. *J Nucl Med* 59: 147-153, 2018.
155. Kramer K, Pandit-Taskar N, Humm JL, **Zanzonico PB**, Haque S, Dunkel IJ, Wolden SL, Donzelli M, Goldman DA, Lewis JS, Lyashchenko SK, Khakoo Y, Carrasquillo JA, Souweidane MM, Greenfield JP, Lyden D, De Braganca KD, Gilheeny SW, Larson SM, Cheung NV. A phase II study of radioimmunotherapy with intraventricular ^{131}I -3F8 for medulloblastoma. *Pediatr Blood Cancer* 2018.
156. Chen F, Zhang X, Ma K, Madajewski B, Benezra M, Zhang L, Phillips E, Turker MZ, Gallazzi F, Overholtzer M, Pauliah M, Gonen M, **Zanzonico P**, Wiesner UB, Bradbury MS, Quinn T. Melanocortin-1 receptor-targeting ultrasmall silica nanoparticles for dual-modality human melanoma imaging. *ACS Appl Mater Interfaces* 10: 4379-4393, 2018.
157. Ulaner GA, Lyashchenko SK, Riedl C, Ruan S, **Zanzonico PB**, Lake D, Jhaveri K, Zeglis B, Lewis JS, O'Donoghue JA. First-in-human HER2-targeted imaging using ^{89}Zr -pertuzumab PET/CT: Dosimetry and clinical application in patients with breast cancer. *J Nucl Med* 59: 900-906, 2018.
158. Kirov AS, Fanchon LM, Seiter D, Czmielowski C, Russell J, Dogan S, Carlin S, Pinker-Domenig K, Yorke E, Schmidlein CR, Boyko V, Fujisawa S, Manova-Todorova K, **Zanzonico P**, Dauer L, Deasy JO, Humm JL, Solomon S. Technical Note: Scintillation well counters and particle counting digital autoradiography devices can be used to detect activities associated with genomic profiling adequacy of biopsy specimens obtained after a low activity ^{18}F -FDG injection. *Med Phys* 45: 2179-2185, 2018.
159. Lin AJ, Karinja SJ, Bernstein JL, Jin J, Toyoda Y, Miller AJ, **Zanzonico PB**, Spector JA. In search of a murine model of radiation-induced periprosthetic capsular fibrosis. *Ann Plast Surg*. 80 (4 Suppl 4): S204-S210, 2018.
160. Vargas HA, Kramer GM, Scott AM, Weickhardt A, Meier AA, Parada N, Beattie BJ, Humm JL, Staton KD, **Zanzonico PB**, Lyashchenko SK, Lewis JS, Yaqub M, Sosa RE, van den Eertwegh AJ, Davis ID, Ackermann U, Pathmaraj K, Schuit RC, Windhorst AD, Chua S, Weber WA, Larson SM, Scher HI, Lammertsma AA, Hoekstra O, Morris MJ. Reproducibility and repeatability of semi-quantitative ^{18}F -fluorodihydrotestosterone (FDHT) uptake metrics in castration-resistant prostate cancer metastases: a prospective multi-center study. *J Nucl Med*. 2018 [Epub ahead of print].

161. Cheal SM, Ruan S, Veach DR, Longo VA, Punzalan BJ, Wu J, Fung EK, Kelly MP, Kirshner JR, Giurleo JT, Ehrlich G, Han AQ, Thurston G, Olson WC, **Zanzonico PB**, Larson SM, Carrasquillo JA. ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts. *Mol Pharm* 15: 2133-2141, 2018.
162. Souweidane MM, Kramer K, Pandit-Taskar N, Zhou Z, Haque S, **Zanzonico P**, Carrasquillo JA, Lyashchenko SK, Thakur SB, Donzelli M, Turner RS, Lewis JS, Cheung NV, Larson SM, Dunkel IJ. Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. *Lancet Oncol* S1470-2045, 2018.

II. Conference Proceedings, Chapters, and/or Invited Publications

1. **Zanzonico PB**. The development of ^{11}C -alpha-aminoisobutyric acid and ^{18}F -haloperidol as substrate-specific radiotracers. PhD Dissertation. Cornell University, Graduate School of Medical Sciences, 1982.
2. Bigler RE, Dahl JR, Rothman LS, and **Zanzonico PB**. Compact cyclotron production of 38.1 minute zinc-63 for positron tomography. *In Proceedings of the Fourth International Symposium Radiopharmaceutical Chemistry*, Julich, West Germany, pp 159-160, 1982.
3. Schmall B, Bigler RE, **Zanzonico PB**, Conti PS, Dahl JR, and Lee R. Tumor visualization and pharmacokinetic studies with C-11-alpha-aminoisobutyric acid (AIB) in dogs bearing spontaneous cancers. *In Raynaud C (ed), Proceedings of the Third World Congress of Nuclear Medicine and Biology*, Paris, Pergamon Press, pp 3204-3207, 1982.
4. Sacks W, Hammer B, Bigler RE, Cowburn D, Sacks S, Fleischer A, **Zanzonico PB**, Badalamenti A, and Hennessy M. The use of ^{13}C -glucose and NMR to study cerebral carbohydrate metabolism in vivo in the rat and Rhesus monkey. *In PET and NMR: New Perspectives in Neuroimaging and in Clinical Neuro-chemistry*, Alan Liss, New York, pp. 283-302, 1986.
5. **Zanzonico PB**, Bigler RE, Primus FJ, Alger E, DeJager R, Stowe S, Ford E, Brennan K, and Goldenberg D. A compartmental modeling approach to the radiation dosimetry of radiolabeled antibody. *In Schlafke-Stelson AT and Watson E (Eds), Proceedings of the Fourth International Radiopharmaceutical Dosimetry Symposium*, Oak Ridge, TN, US Dept of Energy and Oak Ridge Associated Universities (Conf-85113 (DE86010102), pp 421-445, 1986.
6. Bigler RE, **Zanzonico PB**, Primus FJ, Alger E, DeJager R, Stowe S, Ford E, Goldenberg DM, Leonard R, and Cosma M. Some marrow dosimetry for monoclonal antibody therapy. *In Schlafke-Stelson AT and Watson E (Eds), Proceedings of the Fourth International Radiopharmaceutical Dosimetry Symposium*, Oak Ridge, TN, US Dept of Energy and Oak Ridge Associated Universities (Conf-85113 (DE86010102), pp 535-544, 1986.

7. Bigler RE, **Zanzonico PB**, Cosma M, and Sgouros G. Adjuvant radioimmunotherapy: A strategy for cancer cure. *In* Srivastava SC (Ed), Radiolabeled Monoclonal Antibodies for Imaging and Therapy, New York, Plenum Press, pp 409-429, 1988.
8. **Zanzonico PB**, Bigler RE, Sgouros G, and Strauss, A. Quantitative SPECT in radiation dosimetry. *Sem Nucl Med* 19: 47-61, 1989.
9. **Zanzonico PB**, Edwards C, Sgouros G, Strauss A, Bigler RE, Hurley JR, and Becker DV. Practical dosimetry: Quantitative imaging in radionuclide therapy. *In* Adelstein SJ, Kassis AI, and Burt RW (Eds), Dosimetry of Administered Radionuclides, American College of Nuclear Physicians, Washington, DC, 1989.
10. **Zanzonico PB** and Becker DV. Radiation hazards in children born to mothers exposed to 131-iodine. *In* Beckers C and Reinwein D (Eds), The Thyroid and Pregnancy, Stuttgart, Schattauer, pp 189-202, 1991.
11. Becker DV, **Zanzonico PB**, Hurley JR, Kusic Z, Sanderson L, Tsen O, and Strauss A. Treatment of hyperthyroidism with 131-I: Continuation of antithyroid drugs does not adversely affect therapy and in "small pool" patients reduces the extrathyroidal radiation dose. *In* Gordon A, Gross J, and Henneman G (Eds), Progress in Thyroid Research, Balkema, Rotterdam, pp 223-226, 1991.
12. **Zanzonico PB** and Becker DV. Use of potassium iodide to minimize thyroid radiation from radioactive fall-out. *In* Delange F, Dunn JT, and Glinoe D (Eds), Workshop on Iodine Deficiency in Europe: A Continuing Concern, Brussels, Plenum Press, New York, pp 243-253, 1993.
13. Becker DV and **Zanzonico PB**. Radioiodine therapy in children. *In* Robbins J (Ed), Treatment of Thyroid Cancer in Childhood, Bethesda, MD, National Institutes of Health (DOE/EH-0406), pp 117-125, 1993.
14. **Zanzonico PB**. Radioimmunotherapy in micrometastases: A continuing evolution. *J Nucl Med* 33: 2180-2183, 1992.
15. **Zanzonico, PB**. Technical requirements for SPECT: Equipment and quality control. *In* Kramer EL and Sanger JJ (Eds), Clinical Applications in SPECT, Raven Press, New York, pp 7-41, 1995.
16. Herrold EM, Goldfine SM, Zhou H, Cooper AJL, Nakayama S, **Zanzonico P**, Magid N, and Borer JS. Computer-based algorithm modeling protein metabolism in aortic regurgitation for positron emission tomography. *In* Proceedings of Computers in Cardiology, Bethesda, MD, pp 389-392, Sept 25-28, 1994.
17. Szulc M, Herrold Em, **Zanzonico P**, and Borer JS. Ejection fraction with planar gated 99m-Tc SestaMIBI images. *In* Proceedings of Computers in Cardiology, Bethesda, MD, pp 521-524, Sept 25-28, 1994.

18. **Zanzonico PB**, Brill AB, and Becker DV. Radiation dosimetry. *In* Wagner H (Ed), Principles of Nuclear Medicine, 2nd ed, WB Saunders, Philadelphia, PA. pp 106-134, 1995.
19. **Zanzonico PB**. Book review: Radiation Protection in the Health Sciences. *J Nucl Med* **37**: 1921-1922, 1996.
20. Becker DV and **Zanzonico PB**. Potassium iodide for thyroid blockade in a reactor accident: Administrative policies that govern its use. Proceedings of the International Symposium on Radioiodine, Rochester, MN, August 24-27, 1996, *Thyroid* **7**: 199-204, 1997.
21. **Zanzonico PB**. Radiation dose to patients and families incident to I131 therapy. Proceedings of the International Symposium on Radioiodine, Rochester, MN, August 24-27, 1996, *Thyroid* **7**: 193-198, 1997.
22. **Zanzonico P** and Sgouros G. Predicting myelotoxicity in radioimmunotherapy: What does dosimetry contribute? *J Nucl Med* **38**: 1753-1754, 1997.
23. **Zanzonico PB** and Becker DV. Iodine nutrition: Considerations of prophylaxis and treatment with regard to nuclear radiation exposure. *In* Stanbury JB, Delange F, Dunn JT, and Pandav CS (Eds), Iodine in Pregnancy, Oxford University Press, Delhi, India, pp 181-201, 1998.
24. **Zanzonico P** and Heller S. The intraoperative gamma probe: Basic principles and choices available. *Sem Nucl Med* **30**: 33-48, 2000.
25. **Zanzonico P**. Internal radionuclide radiation dosimetry: A review of basic concepts and recent developments. *J Nucl Med* **41**: 297-308, 2000.
26. Guenther I, Pentlow KS, **Zanzonico PB**, Finn RD, Polycarpe D, Kang G, Kappel B, O'Donoghue J, Humm J, and Larson SM. Biodistribution and imaging of ⁶⁶Ga-citrate and ⁶⁷Ga-citrate in tumor-bearing nude mice: A comparison. 14th International Symposium on Radiopharmaceutical Chemistry (ISRC), June 10-15, 2001, Interlaken, Germany.
27. Chapman JD, **Zanzonico P**, and Ling C. On measuring hypoxia in individual tumors with radiolabeled agents. *J Nucl Med* **42**: 1653-1655, 2001.
28. **Zanzonico P** and Poston JW. Computational methods in internal radiation dosimetry. *In* Zaidi H and Sgouros G (Eds), Monte Carlo Calculations in Nuclear Medicine: Therapeutic Applications, IOP Publishing Limited, Bristol, England, pp 84-108, 2002.

29. **Zanzonico P.** The intraoperative gamma probe: Design, operation, and safety. *In* Cody H (Ed), Sentinel Lymph Node Biopsy, Martin Dunitz Publishers, London, pp 45-68, 2002.
30. **Zanzonico PB.** Model-based versus patient-specific dosimetry: Blurring the lines. *J Nucl Med* 43: 1665-1666, 2002.
31. Becker DV and **Zanzonico PB.** Radioiodine treatment of thyrotoxicosis. *In* Wass JAH and Shalet SM (Eds), Oxford Textbook of Endocrinology, Oxford University Press, Oxford, *In Press*.
32. **Zanzonico P.** Positron emission tomography: A review of basic principles, scanner design and performance, and current systems. *Sem Nucl Med* 34: 87-111, 2004.
33. **Zanzonico P.** PET-based biological imaging for radiation therapy treatment planning. *Crit Rev Eukaryot Gene Expr* 16:61-101, 2006.
34. **Zanzonico P.** Broad-Spectrum Multi-Modality Image Registration: From PET, CT, and MRI to Autoradiography, Microscopy, and Beyond. *Conf Proc IEEE Eng Med Biol Soc* 1:1584-1588,2006.
35. **Zanzonico P** and Nehmeh SA. Introduction to clinical and laboratory (small-animal) image registration and fusion. *Conf Proc IEEE Eng Med Biol Soc* 1:1580-1583, 2006.
36. **Zanzonico P** and Heller S. Physics, instrumentation, and radiation protection. *In* Biersack HJ and Freeman LM (Eds), Clinical Nuclear Medicine, Springer-Verlga, Berlin, pp 1-33, 2007.
37. **Zanzonico P** and Divgi C. Patient-specific radiation dosimetry for radionuclide therapy of liver tumors with intra-hepatic artery rhenium-188 Lipiodol. *Sem Nucl Med* 38: S30-S39, 2008.
38. Bernal P, Raoul JL, Stare J, Sereegotov E, Sundram, FX, Kumar A, Jeong JM, Pusuwan P Divgi C, **Zanzonico P**, Vidmar G, Buscombe J, Chau TTM, Saw MM, Chen S, Ogbac R, Dondi M, and Padhy AJ. International Atomic Energy Agency (IAEA)-sponsored multination study of intra-arterial rhenium-188 Lipiodol in the treatment of inoperable hepatocellular carcinoma: Results with special emphasis on prognostic value of dosimetric studies. *Sem Nucl Med* 38: S40-S45, 2008.
39. **Zanzonico P.** Radiation dosimetry for targeted radionuclide therapy. *In* Speer T (Ed), Targeted Radionuclide Therapy, Lippincott, Hagarstown, MD, pp 108-128, 2011.
40. **Zanzonico P.** Non-invasive imaging for supporting basic research. *In* Kiessling F, Hauf P, and Pichler B (Eds), Small-Animal Imaging: Basics and Practical Guide, Springer-Verlag, Heidelberg, Germany, pp 3-16, 2011.

41. Heller S and **Zanzonico P** Nuclear probes and introperative gamma cameras. *Sem Nucl Med* 41(3):166-181, 2011.
42. **Zanzonico P**. Cell-level dosimetry and biologic response modeling of heterogeneously distributed radionuclides: a step forward. *J Nucl Med*52: 845-847, 2011
43. **Zanzonico P**. Virtual reality for dose optimization in pediatric nuclear medicine: better than the real thing. *J Nucl Med* 52: 1845-1847, 2011.
44. Balter S, **Zanzonico P**, Reiss GR, and Moses JW. Radiation is not the only risk. *Am J Roentgenol* 196: 762-767, 2011
45. **Zanzonico P**. Principles of nuclear medicine imaging: Planar, SPECT, PET, and multi-modality systems. *Radiat Res* 177: 349-364, 2012.
46. **Zanzonico P**. Instrumentation. *In* Strauss HW, Mariani G, Volteranni G, Larson SM (Eds), Nuclear Oncology: From Pathophysiology to Clinical Applications, pp 93-120, Springer, New York, 2013.
47. **Zanzonico P**, Stabin MG. Quantitative benefit-risk analysis of medical radiation exposures. *Semin Nucl Med* 44: 210-214, 2014.
48. **Zanzonico P**. Non-imaging detectors. *In* Palm S and Humm JH (Eds), IAEA Nuclear Medicine Handbook, International Atomic Energy Agency (IAEA), Vienna, Austria, 2014.
49. **Zanzonico PB**. Radionuclide Imaging. *In* Cherry SR, Badawi RD, and Jingi Q (Eds), Essentials of In Vivo Biomedical Imaging, CRC Press, Boca Raton, FL, 2015.
50. **Zanzonico, PB**. The neglected side of the coin: Quantitative benefit-risk analyses in medical imaging. *Health Phys* 110: 301-304, 2016.
51. **Zanzonico P**, Dauer L, Strauss HW. Radiobiology in Cardiovascular Imaging. *JACC Cardiovasc Imaging* 9: 1446-1461, 2016.
52. Weber W, **Zanzonico P**. The controversial linear no-threshold model. *J Nucl Med* 58: 7-8, 2017.
53. **Zanzonico P**. Instrumentation for single-photon emission imaging. *In* Strauss HW, Mariani G, Volteranni G, Larson SM (Eds), Nuclear Oncology: From Pathophysiology to Clinical Applications, 2nd ed, Springer, New York, 2017.
54. **Zanzonico P**. Instrumentation for positron emission imaging. *In* Strauss HW, Mariani G, Volteranni G, Larson SM (Eds), Nuclear Oncology: From Pathophysiology to Clinical Applications, 2nd ed, Springer, New York, 2017.

55. **Zanzonico P.** Instrumentation for intraoperative detection. *In* Strauss HW, Mariani G, Volteranni G, Larson SM (Eds), Nuclear Oncology: From Pathophysiology to Clinical Applications, 2nd ed, Springer, New York, 2017.
56. Moroz MA, **Zanzonico P**, Lee JT, Ponomarev V. Ex Vivo Radiolabeling and In Vivo PET Imaging of T Cells Expressing Nuclear Reporter Genes. *Methods Mol Biol* 1790:153-163, 2018.
57. **Zanzonico P.** Image registration for multimodality small-animal imaging . *In* Zaidi H (Ed), Multimodality Molecular Imaging of Small-Animals: Instrumentation and Applications, In Press.

III. Abstracts

1. **Zanzonico PB**, Fernandes G, and Good RA. The differential sensitivity of T cell and B cell mitogenesis to in vitro zinc deficiency. *Fed Proc* 39: 3389a,1980.
2. Dunzendorfer U, Schmall B, Bigler RE, **Zanzonico PB**, Conti PS, Dahl JR, Kleinert E, and Whitmore W. Biodistribution studies of 1-¹¹C-alpha-aminoisobutyric acid in rats bearing treated and untreated prostatic tumors. 76th Annual Convention of the American Urological Association, Boston, MA, May 4-6, 1981.
3. Schmall B, **Zanzonico PB**, Bigler RE, Dahl JR, and Lee R. Synthesis of F-18 aryl fluorides with no-carrier-added for the in vivo measurement of the receptor concentrations. National Workshop on the Future of Fluorine Radiopharmaceuticals, 1st Annual Conjoint Winter Conference, Society of Nuclear Medicine, New Orleans, LA, February 5-8, 1981.
4. **Zanzonico PB**, Schmall B, Bigler RE, Conti PS, Kleinert E, Israel E, Dahl JR, and Lee R. Preclinical evaluation of carbon-11 alpha-aminoisobutyric acid (AIB): Tumor imaging with PETT, radiation dosimetry, and toxicology. Society of Nuclear Medicine 28th Annual Meeting, Las Vegas, NV, June 16-19, 1981.
5. Bigler RE, Dahl JR, Rothman L, and **Zanzonico PB**. Compact medical cyclotron preparation of zinc-63 for medical use. Society of Nuclear Medicine 28th Annual Meeting, Las Vegas, NV, June 16-19, 1981.
6. Schmall B, **Zanzonico PB**, Bigler RE, Dahl JR, and Lee R. Synthesis of fluorine-18 aryl fluorides with no-carrier-added as potential agents for the in vivo measurement of receptor concentrations. Society of Nuclear Medicine 28th Annual Meeting, Las Vegas, NV, June 16-19, 1981.
7. Schmall B, **Zanzonico PB**, Bigler RE, Dahl JR, and Lee R. Synthesis of fluorine-18 aryl fluorides as receptor-mediated radiotracers: Preparation of fluorine-18 haloperidol with no-carrier-added. 182nd Meeting of the American Chemical Society, New York, NY, August 23-27, 1981.

8. Bigler RE, Dahl JR, and **Zanzonico PB**. Zinc-63: A new radionuclide for positron tomography. American Association of Physicists in Medicine 23rd Annual Meeting, Boston, MA, August 9-13, 1981.
9. **Zanzonico PB**, Schmall B, Bigler RE, Conti PS, Kleinert E, Laurs A, Rothman LS, and Dahl JR. The pharmacokinetics of C-11 alpha-aminoisobutyric acid - A potential agent for tumor imaging and for in vivo quantitation of amino acid transport. 2nd International Symposium on Radiopharmacology, Chicago, IL, September 9-11, 1981.
10. Schmall B, Conti PS, Bigler RE, **Zanzonico PB**, Jacobsen JK, and Lee R. Synthesis of C-11 benzoate for physiological and metabolic studies: Evaluation in tumor-bearing animals, 183rd National Meeting of the American Chemical Society, Las Vegas, NV, March 28-April 2, 1982.
11. **Zanzonico PB**, Bigler RE, and Schmall B. Specific labeling in vivo of dopamine receptors using F-18 haloperidol. 8th Annual Scientific Meeting of the Greater New York Chapter of the Society of Nuclear Medicine, New York, NY, September 10-12, 1982.
12. Bigler RE, Rothman L, Heller A, Dahl JR, Tannenbaum J, **Zanzonico PB**, and Rivlin RS. Direct measurement of jejunal absorption of zinc in humans using ⁶³Zn. 1983 Meeting of the American Society of Clinical Nutrition, Washington, DC, April 29-May 2, 1983.
13. **Zanzonico PB**, Bigler RE, and Schmall B. Specific labeling in vivo of murine neuroleptic binding sites using ¹⁸F-haloperidol, a potential non-invasive probe for psychiatric disease. Society of Nuclear Medicine 30th Annual Meeting, St. Louis, MO, June 7-10, 1983.
14. Bigler RE, **Zanzonico PB**, and Sgouros G. Compartmental model for in vivo assessment of A-type amino acid transport. Society of Nuclear Medicine 30th Annual Meeting, St. Louis, MO, June 7-10, 1983.
15. Hammer BE, Sacks W, Hennessy MJ, Bigler RE, Sacks S, Fleischer A, and **Zanzonico PB**. In vivo C-13 NMR of glucose in monkey brains. Society of Magnetic Resonance in Medicine 3rd Annual Meeting, San Diego, CA, March 22-26, 1985.
16. Bigler RE, Sgouros G, **Zanzonico PB**, Cosma M, Leonard RW, and Dahl JR. Radiation dose to the respiratory airway linings from inhalation of ¹⁵O-carbon dioxide. Society of Nuclear Medicine 32nd Annual Meeting, Houston, TX, June 2-5, 1985.
17. **Zanzonico PB**, Bigler RE, Leonard RW, and Sacks W. The enzymatic basis of the biodistribution of FDG: Implications for tumor imaging. Society of Nuclear Medicine 32nd Annual Meeting, Houston, TX, June 2-5, 1985.

18. Conti PS, Schmall B, Bigler RE, **Zanzonico PB**, Kleinert E, and Whitmore WF. Accumulation of D- vs L- isomers of alanine and leucine in rat prostatic adenocarcinoma. Society of Nuclear Medicine 32nd Annual Meeting, Houston, TX, June 2-5, 1985.
19. Welt S, Grando R, Mattes MJ, Thomson TM, Leonard RW, **Zanzonico PB**, Bigler RE, Yeh S, Oettgen L, and Old L. Monoclonal antibody localization to a cytoplasmic antigen of melanoma heterotransplants in nu/nu mice: Imaging at 8-10 weeks. 1986 American Society of Clinical Oncology Annual Meeting, Los Angeles, CA, May 4-6, 1986.
20. **Zanzonico PB**, Bigler RE, Hurley JR, Becker DV, and Edwards C. The use of quantitative SPECT and physiological modeling for thyroid cancer. "Metabolic Imaging with NMR, SPECT, and PET," West Palm Beach, FL, March 3-5, 1986.
21. Bigler RE, **Zanzonico PB**, and Cosma M. Microdosimetric and compartmental analysis of a novel strategy for curative radioimmunotherapy. Society of Nuclear Medicine 33rd Annual Meeting, Washington, DC, June 22-25, 1986.
22. Yankelevitz D, Tsen O, **Zanzonico PB**, Sarkar S, Edwards C, Riehle R, and Connors D. Radiohippurate renography in patients undergoing extracorporeal shock wave lithotripsy (ESWL). Society of Nuclear Medicine 33rd Annual Meeting, Washington, DC, June 22-25, 1986.
23. Bigler RE, **Zanzonico PB**, Cosma M, and Sgouros G. Adjuvant radioimmunotherapy: A strategy for cancer cure. NATO Advanced Study Institute, "Radiolabeled Antibodies for Imaging and Therapy," Barga, Italy, July 20-August 1, 1986.
24. Hammer BE, Sacks W, Bigler RE, Hennessy MJ, Sacks S, Fleischer A, and **Zanzonico PB**. In-vivo metabolism of (C-13)-1-glucose in monkey brain by C-13 NMR spectroscopy, Society of Magnetic Resonance in Medicine 5th Annual Meeting, Montreal, Canada, August 18-22, 1986.
25. Sgouros G, **Zanzonico PB**, Bigler RE, and Sacks W. Quantitation of radiation induced changes in cerebral glucose metabolism using ^{13}C NMR spectroscopy and (1- ^{13}C)-glucose. Society of Magnetic Resonance in Medicine 5th Annual Meeting, Montreal, Canada, August 18-22, 1986.
26. Hammer BE, Sacks W, Bigler RE, Hennessy MJ, Sacks S, Fleischer A, and **Zanzonico PB**. In-vivo metabolism of [(C-13)-1]-glucose in monkey brain by C-13 NMR spectroscopy. "Physiological NMR Spectroscopy: From Isolated Cells to Man", New York Academy of Sciences, New York, September 24-26, 1986.
27. Sgouros G, Bigler RE, **Zanzonico PB**, and Tsen O. IMPACS: Integrated nuclear medicine information management and PACS. 72nd Scientific Assembly and Annual Meeting of the Radiological Society of North America, Chicago, November 30-December 5, 1986.

28. Berkman Y, Yankelevitz D, and **Zanzonico PB**. Torsion of the upper lobe in pneumothorax: A normal phenomenon. 87th Annual Meeting of the Roentgen Ray Society, Miami Beach, FL, April 26-May 1, 1987.
29. Bigler RE, **Zanzonico PB**, Sgouros G, and Strauss A. General procedure for treatment planning for curative adjuvant radioimmunotherapy (Illustrated for I-123). Society of Nuclear Medicine 34th Annual Meeting, Toronto, Canada, June 2-5, 1987.
30. Sgouros G, Bigler RE, and **Zanzonico PB**. Techniques for the direct determination of cumulated activity from computer simulations of linear and non-linear compartmental models. Society of Nuclear Medicine 34th Annual Meeting, Toronto, Canada, June 2-5, 1987.
31. Sgouros G, Bigler RE, and **Zanzonico PB**. Compartmental model simulations of antibody kinetics: What parameters most influence antibody dosimetry? Society of Nuclear Medicine 34th Annual Meeting, Toronto, Canada, June 2-5, 1987.
32. **Zanzonico PB**, Becker DV, Bigler RE, and Katz M. Fetal radiation dosimetry for maternally administered I131-iodide: Effect of maternal thyroid function. Society of Nuclear Medicine 34th Annual Meeting, Toronto, Canada, June 2-5, 1987.
33. **Zanzonico PB**, Becker DV, Bigler RE, and Katz M. Thyroid scintigraphy in congenital hypothyroidism: Compartmental analysis-and phantom imaging-based analysis of the minimum administered activity required. Society of Nuclear Medicine 34th Annual meeting, Toronto, Canada, June 2-5, 1987.
34. Bigler RE, **Zanzonico PB**, Sgouros G, and Strauss A. Dosimetry for radioimmunotherapy. 29th Annual Meeting of the American Association of Physicists in Medicine, Detroit MI, July 19-23, 1987.
35. **Zanzonico PB**, Becker DV, Hurley JR, and Katz M. Neonatal thyroid scintigraphy in congenital hypothyroidism: Evaluation and optimization of the cost-benefit ratio. 1987 Annual Meeting of the American Thyroid Association, Washington, DC, September, 16-19, 1987.
36. **Zanzonico PB**, Sgouros G, Strauss A, and Bigler RE. Treatment planning for monoclonal antibody therapy: Quantitative planar imaging and its validation using an anthropomorphic phantom. Society of Nuclear Medicine 35th Annual Meeting, San Francisco, CA June 14-17, 1988.
37. Strauss A, Bigler RE, Sgouros G, and **Zanzonico PB**. A tissue-equivalent anthropomorphic phantom for radionuclide dosimetry and imaging studies. Society of Nuclear Medicine 35th Annual Meeting, San Francisco, CA, June 14-17, 1988.

38. Sgouros G, Bigler RE, and **Zanzonico PB**. *DOSCAL*: A tumor-incorporating mean absorbed dose calculation program. Society of Nuclear Medicine 35th Annual Meeting, San Francisco, CA, June 14-17, 1988.
39. Sgouros G, Barest G, Thekkumthala J, Chui C, Mohan R, Bigler RE, **Zanzonico PB**, and Strauss A. Treatment planning for monoclonal antibody therapy: Three-dimensional dosimetry for non-uniformly distributed radionuclides. Society of Nuclear Medicine 35th Annual Meeting, San Francisco, CA, June 14-17, 1988.
40. Bigler RE, **Zanzonico PB**, and Sgouros G. Radioimmunotherapy for micrometastases: Treatment planning for astatine-211 (alpha-emitter). Society of Nuclear Medicine 35th Annual Meeting, San Francisco, CA, June 14-17, 1988.
41. Bigler RE, Sgouros G, Strauss A, **Zanzonico PB**, Sacks W, Sacks S, Hammer B, Hennessy M, Cowburn D, and Wang CG. ^{13}C NMR spectroscopy of cerebral glucose metabolism: Applicability to human disease. 189th Meeting of the American Chemical Society, Toronto, Canada, June 5-11, 1988.
42. Becker DV, Hurley JR, **Zanzonico PB**, and Kusic Z. Antithyroid drugs given during ^{131}I treatment maintain clinical control of hyperthyroidism and reduce whole body radiation. 1988 Annual Meeting of the American Thyroid Association, Montreal, Canada, September 27-30, 1988.
43. **Zanzonico PB**, Becker DV, Brill AB, Tsen O, Strauss A, Hurley JR, Sanderson L, Bigler RE, and Bushe H. Extra-thyroidal absorbed doses in radioiodine treatment of hyperthyroidism: Compartmental modeling-based analysis of 468 patients. Society of Nuclear Medicine 36th Annual Meeting, St. Louis, MO, June 13-16, 1989.
44. Bigler RE, **Zanzonico PB**, Sgouros G, Strauss A, and Godwin T. Astatine-211 monoclonal antibody cell cluster (micrometastasis) radiation dosimetry. Society of Nuclear Medicine 36th Annual Meeting, St. Louis, MO, June 13-16, 1989.
45. Sgouros G, Bigler RE, **Zanzonico PB**, and Strauss A. Kinetics of radiolabeled antibody penetration into micrometastatic cell clusters: A model incorporating diffusion, saturable binding, and dissociation. Society of Nuclear Medicine 36th Annual Meeting, St. Louis, MO, June 13-16, 1989.
46. Fine EJ, Blaufox MD, Heller SL, Zhang CG, Sarkar S, Rottman J, **Zanzonico PB**, Pickering TG, Mann SJ, and Scesney WA. Captopril (ACEI) induced scintigraphic (SR) changes in hypertensives without renovascular hypertension (RVH). Society of Nuclear Medicine 37th Annual Meeting, Washington, DC, June 19-22, 1990.
47. **Zanzonico PB**, Hurley JR, and Becker DV. Quantitation in radioiodine therapy of metastatic thyroid cancer: Comparison of projected and actual tumor absorbed doses. Society of Nuclear Medicine 37th Annual Meeting, Washington, DC, June 19-22, 1990.

48. Bigler RE, **Zanzonico PB**, Sgouros G, Strauss A, and Godwin TA. Feasibility dosimetry for radioimmunotherapy of micrometastases (RIMM). Society of Nuclear Medicine 37th Annual Meeting, Washington, DC, June 19-22, 1990.
49. Sgouros G, Bigler RE, Strauss A, Sacks W, Sacks S, and **Zanzonico PB**. Radiation-induced activation of the pentose phosphate pathway in rat brain. Society of Nuclear Medicine 37th Annual Meeting, Washington, DC, June 19-22, 1990.
50. **Zanzonico PB**, Becker DV, Hurley JR, Kusic Z, Sanderson L, Go S, Tsen O, and Strauss A. Enhancement of radioiodine therapy of hyperthyroidism in "small pool" patients: Dosimetric methodology and results. Society of Nuclear Medicine 38th Annual Meeting, Cincinnati, OH, June 11-14, 1991.
51. Goldfine SM, Cooper AJL, Gelbard AS, Herrold EM, **Zanzonico P**, Magid NM, and Borer JS. Evaluation of myocardial protein synthesis by positron emission tomography (PET): A preliminary analysis using [1-¹⁴C]leucine for modeling. Society of Nuclear Medicine 38th Annual Meeting, Cincinnati, OH, June 11-14, 1991.
52. Goldfine SM, Cooper AJL, Gelbard AS, Herrold EM, **Zanzonico P**, Magid NM, Carter J, and Borer JS. Evaluation of myocardial protein synthesis by positron emission tomography (PET): A preliminary analysis using [1-¹⁴C]leucine for modeling. American Federation for Clinical Research - Eastern Section, Eastern Society for Pediatric Research, and Society for Investigative Dermatology - Eastern Region 1991 Meeting, New York, NY, October 4-5, 1991.
53. Herrold EM, Goldfine SM, **Zanzonico PB**, Cooper AJL, Gelbard AS, Magid NM, and Borer JS. Myocardial protein metabolism: Potential importance of including plasma α-ketoglutarate in a [1-¹⁴C]leucine model for positron emission tomography. American College of Cardiology 1992 Meeting, Dallas, TX, April 13-16, 1992.
54. Hardoff R, Braegelman F, **Zanzonico P**, Herrold EM, Lees RS, Lees AM, Dean R, Lister-James J, and Borer JS. Atherosclerosis imaging with I-123 SP4: In vivo - ex vivo correlation. 1992 Annual Meeting of the Association of American Physicians, American Society for Clinical Investigation, and American Federation for Clinical Research, Baltimore, MD, May 1-4, 1992.
55. Hardoff R, Braegelman F, **Zanzonico P**, Herrold EM, Lees RS, Lees AM, Dean R, Lister-James J, and Borer JS. Imaging atherosclerosis with I-123 SP4. Society of Nuclear Medicine 39th Annual Meeting, Los Angeles, CA, June 9-12, 1992.
56. Hardoff R, **Zanzonico P**, Braegelman F, Herrold EM, Lees RS, Lees AM, Lister-James J, Dean R, and Borer JS. Accumulation of Tc-99m in atherosclerotic lesions in aorta and carotid arteries in Watanabe hyperlipidemic rabbits. American Federation for Clinical Research - Eastern Section, Eastern Society for Pediatric Research, and Society for Investigative Dermatology - Eastern Region 1992 Meeting, New York, NY, October 9-10, 1992.

57. Hardoff R, **Zanzonico P**, Braegelman F, Herrold EM, Lees RS, Lees AM, Lister-James J, Dean R, and Borer JS. Autoradiographic identification of atherosclerosis with I-125 SP-4. American Federation for Clinical Research - Eastern Section, Eastern Society for Pediatric Research, and Society for Investigative Dermatology - Eastern Region 1992 Meeting, New York, NY, October 9-10, 1992.
58. Goldfine SM, Herrold EM, Cooper AJL, Magid NM, **Zanzonico P**, Gelbard, and Borer JS. Modeling of cardiac protein metabolism for positron emission tomography in mild-to-moderate aortic regurgitation. American Federation for Clinical Research - Eastern Section, Eastern Society for Pediatric Research, and Society for Investigative Dermatology - Eastern Region 1992 Meeting, New York, NY, October 9-10, 1992.
59. Hardoff R, **Zanzonico P**, Braegelman F, Herrold EM, Lees RS, Lees AM, Lister-James J, Dean R, and Borer JS. Accumulation of Tc-99m in atherosclerotic lesions in aorta and carotid arteries in Watanabe hyperlipidemic rabbits. 65th Scientific Session of the American Heart Association, New Orleans, LA, November 16-19, 1992.
60. Hardoff R, **Zanzonico P**, Braegelman F, Herrold EM, Lees RS, Lees AM, Lister-James J, Dean R, and Borer JS. Autoradiographic identification of atherosclerosis with I-125 SP-4. 65th Scientific Session of the American Heart Association, New Orleans, LA, November 16-19, 1992.
61. Hardoff R, **Zanzonico P**, Braegelman F, Lu P, Herrold EM, Lees RS, Lees AM, Lister-James J, Dean R, and Borer JS. Atherosclerosis imaging with Tc-99m labeled ApoB synthetic peptides in hyperlipidemic rabbits. Society of Nuclear Medicine 40th Annual Meeting, Toronto, Canada, June 8-11, 1993.
62. **Zanzonico P**. The fallacy of the chest x-ray as a basis for comparing radiogenic risks. Society of Nuclear Medicine 40th Annual Meeting, Toronto, Canada, June 8-11, 1993.
63. Lu P, **Zanzonico P**, Goldfine S, Hardoff R, Braegelman F, Wallerson D, Magid N, Herrold EM, and Borer JS. Antimyosin antibody imaging in experimental aortic regurgitation. *Circulation* 88: 1342, Part 2, 1993.
64. Goldfine SM, Herrold EM, **Zanzonico P**, Cooper AJL, Magid NM, Gelbard AS, Zhou H, and Borer JS. Modeling cardiac protein metabolism for positron emission tomography. 1st International Congress of Nuclear Cardiology, Cannes, France, April 25-28, 1993.
65. Hardoff R, **Zanzonico P**, Braegelman F, Herrold EM, Lees RS, Lees AM, Lister-James J, Dean R, and Borer JS. Accumulation of Tc-99m in atherosclerotic lesions in aorta and carotid arteries in Watanabe heritable hyperlipidemic rabbits. 1st International Congress of Nuclear Cardiology, Cannes, France, April 25-28, 1993.

66. Hardoff R, **Zanzonico P**, Braegelman F, Herrold EM, Lees RS, Lees AM, Lister-James J, Dean R, and Borer JS. Autoradiographic identification of atherosclerosis with I125-SP4. 1st International Congress of Nuclear Cardiology, Cannes, France, April 25-28, 1993.
67. Lu P, **Zanzonico P**, Lister-James J, Herrold E, Lees R, Lees A, Dean RT, and Borer JS. Comparison in rabbits of Tc-99m-labeled synthetic peptide fragments for imaging of atherosclerotic plaques. Society of Nuclear Medicine 41st Annual Meeting, Orlando, FL, June 5-8, 1994.
68. Herrold EM, Goldfine SM, Zhou H, **Zanzonico P**, Cooper AJL, Magid NM, Gelbard AS, and Borer JS. Cardiac protein metabolism: Validation of model in aortic regurgitation for positron emission tomography. Society of Nuclear Medicine 41st Annual Meeting, Orlando, FL, June 5-8, 1994.
69. Khilnani N, Lee M, Winchester P, Sos T, **Zanzonico P**, McCaffery T, Trost D, and Jagust M. In vitro model to evaluate the relative efficacy of several catheter directed thrombolytic strategies: Results of a pilot study. 43rd Annual Meeting of Association of University Radiologists, San Diego, CA, April 4-8, 1995.
70. Lu P, **Zanzonico P**, Lister-James J, Herrold E, Lees RS, Lees AM, Dean RT, and Borer JS. Comparison in rabbits of Tc-99m-labeled synthetic peptide fragments for imaging of atherosclerotic plaques. 2nd International Congress of Nuclear Cardiology, Cannes, France, April 23-26, 1995.
71. Lu P, **Zanzonico P**, Lister-James J, Goldfine SM, Herrold E, Lees RS, Lees AM, Dean RT, and Borer JS. Biodistribution and autoradiographic localization of I-125-labeled synthetic peptide fragments in experimental atherosclerosis. 2nd International Congress of Nuclear Cardiology, Cannes, France, April 23-26, 1995.
72. Lu P, **Zanzonico P**, Goldfine S, Magid N, Herrold EM, and Borer JS. Antimyosin antibody imaging in experimental aortic regurgitation. 2nd International Congress of Nuclear Cardiology, Cannes, France, April 23-26, 1995.
73. Albert Einstein College of Medicine/Cornell University Medical center Collaborative Hypertension Group. Simultaneous OIH and DTPA captopril renography in essential hypertension (EH). Radionuclide in Nephrourology, Santa Fe, NM, May 1-3, 1995.
74. Herrold EM, Lu P, **Zanzonico P**, Magid NM, Goldfine SM, Szulc M, and Borer JS. Radiolabeled antimyosin antibody-mediated detection of myocardial injury in aortic regurgitation: relation to wall stress. 43rd Annual Meeting of the Society of Nuclear Medicine, Denver, CO, June 3-5, 1996.

75. Magovern CJ, Mack CA, Budenbender KT, **Zanzonico P**, Ko W, Sanborn T, Isom OW, Crystal RG, and Rosengart TK. Gene transfer utilizing a replication-deficient adenovirus vector expressing vascular endothelial growth factor protects against acute arterial occlusion in the setting of chronic ischemia. 69th Scientific Session of the American Heart Association, New Orleans, LA, Nov 10-13, 1996.
76. **Zanzonico P**, Mack C, Patel SR, Schwarz EA, Hahn R, Ilercil A, Devereux, Goldsmith SJ, Christian T, Sanborn T, Kovesdi I, Isom OW, Crystal RG, and Rosengart TK. Adenovirus-mediated vascular endothelial growth factor 121 (AdVEGF121) gene therapy in a porcine coronary artery disease (CAD) model assessed with Tc99m-MIBI SPECT. 1997. Society of Nuclear Medicine 44th Annual Meeting, San Antonio, TX, June 1-5, 1997.
77. **Zanzonico P**, Becker DV, and Goldsmith SJ. Release criteria for patients receiving therapeutic amounts of radioactivity: A re-evaluation based on published dosimetry data. Society of Nuclear Medicine 44th Annual Meeting, San Antonio, TX, June 1-5, 1997.
78. Rini JN, Vallabhajosula S, **Zanzonico P**, Hurley JR, Becker DV, and Goldsmith SJ. Society of Nuclear Medicine 44th Annual Meeting, Toronto, Canada, June 7-11, 1998.
79. Lovquist A, **Zanzonico P**, Cheung NK, and Larson S. Compartmental analysis of in vitro cell binding and in vivo biodistribution of I125-3F8 MoAb in tumor-bearing mice: Implications for multi-step targeting. 46th Annual Meeting of the Society of Nuclear Medicine, Los Angeles, CA, June 6-10, 1999.
80. Koehne G; Gallardo HF; **Zanzonico P**; May C; Balatoni J; Tjuvajev J; Blasberg R; Sadelain M, O'Reilly RJ; Larson SM. Noninvasive imaging of radiolabeled antigen-specific human T lymphocytes transduced to express NGFR and hsv-tk after adoptive transfer in scid-mice. *Biology of Blood and Marrow Transplantation* 6: 150, 2000
81. Koehne G, **Zanzonico P**, Gallardo HF, May C, Balatoni J, Tjuvajev J, Blasberg R, Riviera I, O'Reilly RJ, Sadelain M, Larson SM. In Vivo Imaging of Human Radiolabeled Antigen-specific Donor T Lymphocytes after Adoptive Transfer in SCID Mice. Third Annual Meeting of the Society of Gene Therapy, Denver, CO, May 31-June 4, 2000.
82. **Zanzonico P** and Becker DV. A Dose-Response Relationship for Radiation-induced Hypothyroidism in Man. *J Nucl Med (Suppl)* 5: 1048, 2000.
83. Pentlow KS, **Zanzonico PB**, Finn RD, Beattie BJ, O'Donoghue J, Kolbert K, Ling CC, and Larson SM. Imaging and quantitation of 124I and 66Ga with a dedicated small-animal PET scanner. 48th Annual Meeting of the Society of Nuclear Medicine, Toronto, Canada, June 23-27, 2001.

84. Akhurst T, **Zanzonico P**, Homberger F, Beattie B, Blasberg RG, and Larson, SM. Preliminary observations relating to the FDG imaging of mice with the Concorde Microsystems microPET scanner. HiRES 2001: High-resolution Imaging in Small Animals with PET, MR, and Other Modalities: Instrumentation, Applications, and Animal Handling, Rockville, MD, Sept 9-11, 2001.
85. Humm JL, Ballon D, Hu J, Ruan S, Chui C, Tulipano PK, Erdi A, Koucher J, Zakian K, Urano M, **Zanzonico P**, Mattis C, Dyke J, Chen Y, Harrington P, and Ling CC. A stereotactic method for the correlation of biologic images by NMR and PET with tissue histology and autoradiography in animals. HiRES 2001: High-resolution Imaging in Small Animals with PET, MR, and Other Modalities: Instrumentation, Applications, and Animal Handling, Rockville, MD, Sept 9-11, 2001.
86. **Zanzonico P**, Finn R, Schneider R, Chapman JD, Ruan S, Chen Y, Urano M, Beattie B, Keith Pentlow, Larson SM, and Ling CC. MicroPET Imaging of Tumor Hypoxia in a Murine Breast Cancer Model: Direct Comparison of F18-Fluoro-Deoxyglucose (FDG), F18-Fluoro-Misonidazole (FMISO), and I124-Iodo-Azomycin-Galactoside (IAZG). HiRES 2001: High-resolution Imaging in Small Animals with PET, MR, and Other Modalities: Instrumentation, Applications, and Animal Handling, Rockville, MD, Sept 9-11, 2001.
87. **Zanzonico P**, Finn R, Pentlow KS, Erdi Y, Beattie B, Humm J, Akhurst T, Squire O, Morris M, Schr H, McCarthy T, Welch M, and Larson SM. PET-based radiation dosimetry in man of ^{18}F -Fluorodihydrotestosterone (FDHT), a new radiotracer for imaging prostate cancer. J Nucl Med 43(Supplement): 87P, 2002.
88. **Zanzonico PB**, Koehne G, Gallardo H, Balatoni J, Ruan S, Finn R, Galavoni-Tjuvajev J, Blasberg R, Sadelain, O'Reilly RJ, and Larson SM. Dosimetry of genetically modified tumor-specific T cells labeled ex vivo with ^{131}I -FIAU for trafficking studies in vivo. J Nucl Med 43(Supplement): 91P, 2002.
89. Palm S, Emmon RM, Xu S, Matei C, Kolbert KS, Borchardt P, **Zanzonico PB**, Beattie B, Finn RD, Larson SM, Koutcher JA, and Sgouros G. Pharmacokinetics of ^{86}Y -Herceptin in an ovarian carcinoma model: Correlative microPET and MR imaging. J Nucl Med 43(Supplement): 153P, 2002.
90. **Zanzonico P**, Finn R, Schneider R, Chapman JD, Cai S, Chen Y, Ruan S, Urano M, Beattie B, Pentlow KS, Humm J, Larson SM, and Ling C. MicroPET imaging of tumor hypoxia: Direct comparison in tumor-bearing mice of ^{18}F -FDG, ^{18}F -Fluoro-misonidazole (FMISO) and ^{124}I -Iodo-azomycin-galactoside (IAZG), J Nucl Med 43(Supplement): 278P, 2002.
91. Santos EB, Smith-Jones PM, Punzalan BJ, Forster GJ, Punzalan BJ, **Zanzonico P**, Axworthy D, Theodore L, and Larson SM. CC49 single-chain antibody-streptavidin fusion protein pretargeted localization of prostate and colorectal tumors. American Association for Cancer Research. Toronto, Ontario, Canada, April 5-9, 2003.

92. **Zanzonico P**, Cai S, Wen B, Finn R, Ruan S, Beattie B, Pugachev A, Humm J, Larson SM, and Ling C. Comparative microPET tumor imaging of F18-labeled fluoro-deoxyglucose (FDG) and fluoro-misonidazole (FMiso) using animal-specific positioning molds. Society of Nuclear Medicine 50th Annual Meeting, New Orleans, LA, June 21-25, 2003.
93. **Zanzonico P**, Chapman JD, Schneider R, Cai S, Chen Y, Finn R, Ruan, Humm J, Larson SM, and Ling C. Radiation dosimetry of iodine-124-labeled iodo-azomycin galactopyranoside (I124-IAZGP), a new hypoxia PET tracer. Society of Nuclear Medicine 50th Annual Meeting, New Orleans, LA, June 21-25, 2003.
94. Chaudakshetrin P, Osorio M, Sundram FX, Somanesan S, Padhy TAK, C. Divgi C, **Zanzonico P**. Rhenium-188-Lipiodol therapy of liver Cancer: Optimization Of conjugate-view imaging of Re188 for patient-specific dosimetry. Society of Nuclear Medicine 50th Annual Meeting, New Orleans, LA, June 21-25, 2003.
95. Förster GJ, Santos EB, Smith-Jones PB, **Zanzonico P**, Axworthy D, Theodore LJ, and Larson SM. Localization of pancreatic tumors with CC49 single-chain antibody-streptavidin fusion protein (cc49-sa) in a multi-step-targeting (MST) approach. Society of Nuclear Medicine 50th Annual Meeting, New Orleans, LA, June 21-25, 2003.
96. Doubrovin MM, Doubrovina ES, **Zanzonico P**, and Blasberg RG. Monitoring human cytotoxic T-lymphocytes transfected with a reporter human nor-epinephrine transporter gene. Society of Nuclear Medicine 50th Annual Meeting, New Orleans, LA, June 21-25, 2003.
97. Bernal PI, Osorio M, Esguerra R, Ucros G, Divgi C, **Zanzonico P**, and Padhy AK. Evaluation of Rhenium-188 Lipiodol dosimetry in the treatment of liver cancer: experience in Colombia. Society of Nuclear Medicine 51st Annual Meeting, Philadelphia, PA, June 19-23, 2004.
98. Förster GJ, Santos EM, **Zanzonico P**, Smith-Jones P, Axworthy D, Theodore LJ, Larson SM. Pre-targeting with an anti-TAG-72-streptavidin immune construct for radioimmunotherapy: Long-term tumor targeting, kidney activity and biodistribution and autoradiography in multiple xenograft models. Society of Nuclear Medicine 51st Annual Meeting, Philadelphia, PA, June 19-23, 2004.
99. Förster GJ, **Zanzonico P**, Santos EM, Smith-Jones P, Humm JL, Axworthy D, Theodore LJ, Larson SM. Improved renal dosimetry of radiolabeled DOTA-biotin in pre-targeted radioimmunotherapy with a succinylated single-chain antibody/streptavidin construct: In vivo evaluation in rats by serial high-resolution "microSPECT." Society of Nuclear Medicine 51st Annual Meeting, Philadelphia, PA, June 19-23, 2004.
100. Lee DJ, Chaudakshetrin P, La Perle KMD, Larson SM, **Zanzonico PB**, Humm JL. Sub-organ distribution and kinetics of ¹⁶⁶Ho-DOTMP in the rat kidney. Society of Nuclear Medicine 51st Annual Meeting, Philadelphia, PA, June 19-23, 2004.

101. Humm JL, Kramer K, Cheung NKV, Palm S, **Zanzonico P**, Pentlow K, Yeh S, Larson SM. Dosimetry to the cerebral spinal fluid following the intrathecal injection of I-131-labeled 3F8 antibody in patient with leptomeningeal tumors. Society of Nuclear Medicine 51st Annual Meeting, Philadelphia, PA, June 19-23, 2004.
102. Zuckier, LS, Patel VB, **Zanzonico P**. Synthetic FDG PET hepatic lesions for evaluation of image display and perception. Society of Nuclear Medicine 2008 Annual Meeting, New Orleans, LA, June 5-10, 2010.
103. Bartlett RM, Zanzonico PB, Carlin S, Chen Q, Rovle R, O'Donoghue JA, Beattie BJ, Narayanan M, Goergi J, Humm JL. Kinetic modeling of [18F]-FMISO microPET data and its correlation with image-guided pO₂ measurements. Society of Nuclear Medicine 2010 Annual Meeting, Salt Lake City, UT, June 14-18, 2010.
104. Bradbury M, Penate-Medina O, Benezra M, **Zanzonico P**, Schaer D, Ow H, Larson SM, Weisner U. Tumor-selective targeting using multi-modal silica nanoparticle probes for clinical translation. Clinical and Translation Science, A-172, 2010.
105. Ackerstaff E, Cho HJ, Carlin S, Rizwan A, Suehiro M, Ouerfelli O, **Zanzonico PB**, John L, Humm JL, Koutcher JA. Hypoxia Imaging in Cancer – Preclinical Studies. International Conference on Radiation Biology: Nanotechnology, Imaging Science and Stem cell Research in Radiation Oncology, Chennai, India, Nov 15-17, 2010.
106. Ackerstaff E, Suehiro M, Kruchevsky N, Carlin S, Rosenfeld ER, Burgman P, Ouerfelli O, **Zanzonico P**, Zakian KL, Ling CC, Koutcher JA. Trifluoromisonidazole measures hypoxia - An in vivo and in vitro multimodality study. International Society for Magnetic Resonance in Medicine (SMRM) 19th Annual Meeting & Exhibition, Montreal, Quebec, Canada, May 7-13, 2011.
107. Schwartz J, Rimner A, Schöder H, **Zanzonico P**, Humm JL, Nehmeh S. Kinetic analysis of simultaneous dynamic pet imaging of ¹⁸F-MISO and ¹⁸F-FDG: A proof of principle. Society of Nuclear Medicine 2017 Annual Meeting, Denver, June 10-14, 2017.
108. Cheal SM, Fung EK, Xu H, Guo HF, Patel M, Bell M, Kalidindi TM, Punzalan B, **Zanzonico P**, Wittrup KD, Larson SM, Cheung NKV. Comparative efficacy and toxicity of ¹⁷⁷Lu- or ⁹⁰Y-theranostic anti-HER2/anti-DOTA(metal) pretargeted radioimmunotherapy (anti-HER2 DOTA-PRIT) of HER2-expressing breast cancer with curative intent. Society of Nuclear Medicine 2017 Annual Meeting, Denver, June 10-14, 2017.
109. O'Donoghue JA, Lohrmann LGC, O'Reilly E, Yu K, Lowery M, Lyaschenko S, Pandit-Taskar N, Ruan S, Wu L, **Zanzonico P**, Schmidlein CR, Carrasquillo JA, Hansen D, Maffuid P, Lewis J, Weber W. Biodistribution and radiation dose estimates for ⁸⁹Zr-DFO-HuMab-5B1 (MVT-2163) in patients with CA19-9 positive pancreatic cancer. Society of Nuclear Medicine 2017 Annual Meeting, Denver, June 10-14, 2017.

110. Chen F, Ma K, Zhang L, **Zanzonico P**, Wiesner U, Bradbury MS. Multimodality Tumor Imaging Using Clinically-translated Ultrasmall Silica Nanoparticles labeled with Zirconium-89: Comparison of Radiolabeling Strategies. Society of Nuclear Medicine 2017 Annual Meeting, Denver, June 10-14, 2017
111. Vargas HA, Kramer GM, Scott AM, Weickhardt A, Meier A, Parada N, Beattie BJ, Humm J, Staton KD, **Zanzonico P**, Lyashchenko S, Lewis J, Yaqub M, Sosa R, van den Eertwegh AJ, Schuit RC, Windhorst AD, Chua S, Weber W, Larson S, Scher H, Lammertsma AA, Hoekstra OS, Morris MJ. Reproducibility and repeatability of quantitative ^{18}F -fluorodihydrotestosterone (FDHT) uptake metrics in castration resistant prostate cancer metastases: a prospective multi-center study. 12th World Congress of the World Federation of Nuclear Medicine and Biology, April 20-24, 2018.

IV. Invited Presentations

1. "Neuroreceptor Imaging." Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, NY, 1983.
2. "The Enzymatic Basis of the Characteristic Tissue Distribution of the Glucose Analogs DG and FDG - Implications for the Radio-Diagnosis of Cancer." Clinical Nutrition Research Unit, Memorial Sloan-Kettering Cancer Center, New York, NY, 1984.
3. "Quantitation of Planar Radionuclide Imaging Studies." APEX Users' Group Meeting, West Palm Beach, FL, 1986.
4. "Quantitation of SPECT Studies." APEX Users' Group Meeting, New York, NY, 1986.
5. "Non-Invasive Evaluation of Metabolic Parameters of Thyroid Carcinoma." Clinical Nutrition Research Unit, Memorial Sloan-Kettering Cancer Center, New York, NY, 1986.
6. "Current Cameras and Quality Assurance." 3rd Northeast Regional Meeting of the Society of Nuclear Medicine, New York, NY, October 1986.
7. "Internal Radionuclide Dosimetry - The Next Generation." Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, NY, December 1986.
8. "Dosimetric Aspects of Radioiodine Therapy of Thyroid Disease." Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, NY, December 1987.
9. "Compartmental Modeling-Based Kinetic and Dosimetric Analysis of Radioimmunotherapy." Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, NY, September 1988.
10. "Practical Dosimetry: Quantitative Imaging in Radionuclide Therapy." Society of Nuclear Medicine - American College of Nuclear Physicians Joint Symposium, Frontiers in Nuclear Medicine Series: Dosimetry of Administered Radionuclides, Washington, DC, September 1989.
11. "Captopril Renography in Renovascular Hypertension." Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, NY, December 1990.
12. "Dosimetric Aspects of Radioiodine Treatment of Thyroid Cancer." Nuclear Medicine Seminar, Mount Sinai Medical Center, New York, NY, February 1991.
13. "Captopril Renography in Renovascular Hypertension." Clinical Nutrition Research Unit Monthly Meeting, Memorial Sloan-Kettering Cancer Center, New York, NY, April 1991.
14. "PET." First Seminar in Clinical/Radiology Research, Snowbird, UT, April 1992.

15. "Formulation of Appropriate Data Base." Second Seminar in Clinical/Radiology Research, New York, NY, October 1992
16. "Imaging of Atherosclerosis," Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, NY, November 1992.
17. "Quantitative Radionuclide Imaging," Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, NY, January 1993.
18. "Technical Aspects of I-131 Treatment of Thyroid Cancer." North Shore University Hospital-Cornell Medical College, Manhasset, NY, January 1993.
19. "Perinatal Radionuclide Irradiation: Dosimetry and Consequences." Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, NY, October 1994.
20. "Medical Management of a Patient with Thyroid Cancer on Dialysis" (with Dr. James R Hurley). Nuclear Medicine Grand Rounds North Shore University Hospital, October 1995.
21. "The Fallacy of the Chest X-Ray as Basis for Inter-Comparison of Radiogenic Risks." Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, NY, February 1996.
22. "Quality Assurance and Practical Radiation Dosimetry in Internal Radionuclide Therapy." American Association of Physicists in Medicine 38th Annual Meeting and Exhibition, Philadelphia, PA, June 1996.
23. "Radiation Doses to Patients and Relatives Incident to I131 Therapy." International Symposium on Radioiodine, Mayo Clinic, Rochester, MN, August 1996.
24. Discussant of "Coincidence Hybrid SPECT/PET Scintigraphy" by Dr. Martin Sandler, Section of Nuclear Medicine and Bioengineering, New York Academy of Medicine, March 1997.
25. "Experimental Adenovirus-mediated Vascular Endothelial Growth Factor (VEGF) Gene Therapy of Coronary Artery Disease Assessed with Perfusion SPECT," Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, NY, April 1998.
26. "The Relative Effectiveness of Radioiodine and External Radiation in the Induction of Thyroid Cancer," Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, NY, October 5, 1998.
27. "Positron-emitting Pharmaceuticals for Imaging of Tumor Hypoxia," Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, NY, April 1999.

28. "The 'New' Release Criteria for Radionuclide Therapy: Implications and Implementation," Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, NY, February 28, 2000.
29. "The MSKCC microPET: Design, Performance, and Initial Results," Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, NY, April 30, 2001.
30. "Radionuclide Therapy of Liver Cancer: Intra-hepatic Artery Rhenium-188 Lipiodol," Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, NY, May 6, 2002.
31. "Thyroid Cancer: I-131 Therapy of Advanced Thyroid Cancer: Patient-Specific Dosimetry," Continuing Education Session, 49th Annual Meeting of the Society of Nuclear Medicine, Los Angeles, CA, June 15-19, 2002.
32. "Non-Invasive Imaging of Tumor Hypoxia," Pediatrics Grand Rounds, Memorial Sloan-Kettering Cancer Center, New York, NY, October 17, 2002.
33. "I131 Therapy of Thyroid Diseases," 16th Annual Meeting of the Northeast Chapter of the Society of Nuclear Medicine, Newport, RI, Nov 1-3, 2002.
34. Discussant of "Image Fusion in Nuclear Medicine" by Dr. Ora Israel, Section of Nuclear Medicine, New York Academy of Medicine, October 22, 2002.
35. "Positron Emission Tomography: Part I. Basic Principles and Part II. Current Systems," Long Island-Jewish Medical Center, April 2003.
36. "Quantitative Imaging and Patient-Specific Dosimetry of Rhenium-188-Lipiodol for Treatment of Liver Cancer," Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, NY, May 19, 2003.
37. "Regulations, Release Criteria and Radiation Protection Measures in I131 Therapy in North America," Continuing Education Session, Society of Nuclear Medicine 50th Annual Meeting, New Orleans, LA, June 21-25, 2003.
38. "Current Status of Tumor Hypoxia Imaging," Nuclear Medicine Seminar, North Shore University Hospital, Manhasset, NY, October 2003.
39. Discussant of "Nuclear Terrorism" by Dr. John Poston, Section of Nuclear Medicine, New York Academy of Medicine, April 2004.
40. "Routine and 'Not-So-Routine' QA of Gamma Cameras," Continuing Education Session, Society of Nuclear Medicine 51st Annual Meeting, Philadelphia, PA, June 19-23, 2004.
41. "Small-Animal PET: Current Status and Future Directions," Continuing Education Session, Society of Nuclear Medicine 51st Annual Meeting, Philadelphia, PA, June 19-23, 2004.

42. Discussant of "PET-CT" by Dr. Gustave von Schulthess, Section of Nuclear Medicine, New York Academy of Medicine, October 5, 2004.
43. "Current Concepts of PET Design," Nuclear Medicine 2004 Symposium, Albert Einstein College of Medicine and Montefiore Medical Center, New York, NY, October 7-10, 2004.
44. "Small-Animal CT and SPECT-CT: Principles and Applications," Recent Advances in Small-Animal Imaging, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, December 14, 2004.
45. "Multi-modality Imaging: What's Driving the Demand?," 2005 microPET Users' Meeting (2005 Academy of Molecular Imaging Annual Conference), Orlando, FL, March 17-18, 2005.
46. "Biological Imaging-Guided Therapy: Targeting Tumor Hypoxia," 2005 Industry Forum (2005 Academy of Molecular Imaging Annual Conference), Orlando, FL, March 19, 2005.
47. "Optical *in vivo* Imaging: Principles and Applications," Mt Sinai Medical Center, New York, NY, March 25, 2005.
48. "Management of Radionuclide Therapy Patients: The 'New' Release Criteria and Other Radiation Safety Issues," American Pharmacists Association 2005 Annual Meeting, Orlando, FL, April 1-5, 2005.
49. "Biological Imaging-Guided Therapy: Targeting Tumor Hypoxia," 2005 Annual Meeting of NE Chapter of American Association of Physicists in Medicine, Salem, MA, June 3, 2005.
50. "Biological Imaging-Guided Therapy: Localizing Tumor Hypoxia," Vanderbilt University, Nashville, TN, November 18, 2005.
51. "Small-Animal Molecular Imaging (microPET) for Non-Invasive Characterization of Experimental Tumors and Their Microenvironment," Albert Einstein College of Medicine, Bronx, NY, December 16, 2005.
52. "Small-Animal Molecular Imaging: Non-Invasive Characterization of Experimental Tumors and Their Microenvironment," American Pharmacists Association 2005 Annual Meeting, San Francisco, CA, March 20, 2006.
53. "Biologically Conformal Radiation Therapy: Validation of Image-Defined Target Volumes," Target Insight II: Innovative Strategies for Target Definition to Enhance the Therapeutic Ratio, Toronto, Canada, May 2-5, 2006.

54. "Recommendations for Patients Treated with Radiopharmaceuticals," RAMP{Spring Symposium, New York, NY, June 10, 2006.
55. "Small-Animal Imaging for Non-Invasive Characterization of Experimental Tumors and Their Microenvironment," Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, NY, September 12, 2006.
56. "MicroPET, MicroSPECT and Corroborating Modalities in Small Animals: The Pathway to Molecular Imaging," Florida Pharmacy Association Academy of Pharmacy Mid-Year Conference, Orlando, FL October 22, 2006.
57. "Prospective for New PET-CT Devices," Nuclear Medicine 2002 Symposium, Albert Einstein College of Medicine and Montefiore Medical Center, New York, NY, November 2-5, 2006.
58. "New PET/CT Devices...and Beyond," Nuclear Medicine Grand Rounds, Mt Sinai Medical Center, New York, NY, January 24, 2007.
59. "Operational Radiation Safety for PET-CT, SPECT-CT, and Cyclotron Facilities," NCRP 2007 Annual Meeting, Arlington, VA, April 16-17, 2007.
60. "Risk-Benefit Analyses for Radiologic Procedures: Looking at Both Sides of the Coin," Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, NY, October 1, 2007.
61. "New PET/CT Devices...and Beyond," Nuclear Medicine Grand Rounds, Montefiore Medical Center, Bronx, NY, February 25, 2008.
62. "Biological Imaging-Guided Conformal Therapy: Localization of Tumor Hypoxia," Nuclear Medicine Grand Rounds, Mt Sinai Medical Center, New York, NY, April 9, 2008.
63. "Small-Animal Imaging Platforms," University of Turku PET Symposium, Turku, Finland, May 22-25, 2008.
64. "PET and Other Animal Imaging Studies: Toward Clinical Applications," Nuclear Medicine Grand Rounds, North Shore University Hospital, Manhasset, NY, April 13, 2009.
65. "Clinical Translation of Small-Animal Imaging Studies," Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, NY, April 20, 2009.
66. "Release of Radioactive Patients: The Patient Experience Perspective," 2009 Society of Nuclear Medicine Meeting Toronto, Canada, June 13-17, 2009.

67. "Routine Gamma Camera Quality Control and Recognition of Image Artifacts," 2009 Northeast Regional Meeting of the Society of Nuclear Medicine Greater New York and New England Chapters, Rye Brook, NY, November 6-8, 2009.
68. "Putting the Risk vs Benefit Balance in Perspective for Physicians and Patients: Putting the Risk in Perspective. Society of Nuclear Medicine 2010 Annual Meeting, Salt Lake City, UT, June 14-18, 2010.
69. "Putting the Risk vs Benefit Balance in Perspective for Physicians and Patients: Putting the Benefit in Perspective. Society of Nuclear Medicine 2010 Annual Meeting, Salt Lake City, UT, June 14-18, 2010.
70. "Quality Control Review: PET, CT, and PET-CT," 20th Annual Nuclear Pharmacy Lecture Program/2010 Midyear Clinical Conference, Florida Pharmacy Association, Orlando, FL, October 2-3, 2010.
71. "Quantitative Risk-Benefit Analyses in Diagnostic Radiology and Nuclear Medicine," Nuclear Medicine Grand Rounds, North Shore University Hospital, Manhasset, NY, Oct 12, 2010.
72. "Radiotherapy and Radiology in the 21st Century: Risks and Benefits - Radiology," RAMPS-GNYCHPS 2010 Spring Symposium, New York, NY, April 30, 2010.
73. "Nuclear Terrorism: Radiologic and Medical Dimensions," Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, NY, January 10, 2011.
74. "NRC Patient Release Criteria," 32nd Annual High-Country Nuclear Medicine Conference, Steamboat Springs, CO, March 11-16, 2011.
75. "The Neglected Side of the Coin: Risk-Benefit Analysis in Nuclear Medicine and Radiology," Nuclear Medicine Section, New York Academy of Medicine, New York, NY, September 13, 2011.
76. "Radiation Exposure from the Fukushima Nuclear Reactors: Likely Clinical Consequences," Plenary Lecture - 81st Annual Meeting of the American Thyroid Association, Indian Wells, CA, October 26-30, 2011.
77. "Radiation Exposure from the Fukushima Nuclear Reactors: Likely Clinical Consequences," Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, NY, November 14, 2011.
78. "Radiation Exposure from the Fukushima Nuclear Reactors Likely Clinical Consequences" Nuclear Medicine Grand Rounds, Mt Sinai Medical Center, New York, NY, March 28, 2012.
79. "Intraoperative Probes and Cameras: Nuclear and Optical," Nuclear Medicine Grand Rounds, North Shore University Hospital, Manhasset, NY, November 12, 2012.

80. "Intraoperative Nuclear and Optical Imaging: The State of the Art," Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, NY, January 14, 2013.
81. "Quantitative Risk-Benefit Analyses in Medical Imaging: What You *Won't* Read in the NY Times," Nuclear Medicine Seminar, Memorial Sloan-Kettering Cancer Center, New York, NY, March 24, 2014.
82. "ImmunoPET: Pharmacokinetics and Pharmacodynamics of Tumor-Targeted Immune Constructs." Nuclear Medicine Grand Rounds, Mt Sinai Medical Center, , New York, NY, May 23, 2014.
83. "Intraoperative Nuclear and Optical Imaging: The State of the Art." Nuclear Medicine Grand Rounds, Mt Sinai Medical Center, New York, NY, May 1, 2015.
84. "The Neglected Side Of The Coin: Quantitative Benefit-Risk Analyses in Medical Imaging," Health Physics Society 60th Annual Meeting July 15, 2015, Indianapolis, IN
85. "Effect of Radiation on Delivery of Anti-Cancer Drugs to Tumors." Nuclear Medicine Grand Rounds, Mt Sinai Medical Center, New York, NY, March 11, 2016.
86. "Research Update: Imaging of Prostate Cancer." Nuclear Medicine Grand Rounds, Mt Sinai Medical Center, New York, NY, July 22, 2016.
87. "Technical and Dosimetric Aspects of the Fukushima and Chernobyl Nuclear Reactor Accidents," 3rd World Congress on Thyroid cancer, Boston, MA, July 28, 2017.

V. Letters-to-the-Editor

1. Riley RJ, Masterson ME, Laughlin JS, St Germain JM, and **Zanzonico PB**. Reply to Hudson and Coleman. Health Phys 44: 579-580, 1983.
2. **Zanzonico PB**, Bigler RE, and Schmall B. Reply to Eckelman and Gibson. J Nucl Med 25: 534-536, 1984.
3. **Zanzonico PB** and Sgouros G. Reply to Charkes. J Nucl Med 39: 522, 1998.
4. **Zanzonico PB**. Response to "Ask-the-Expert" E Mail. Health Physics Society Web Site, May 2001.
5. **Zanzonico PB**. Response to "Ask-the-Expert" E Mail. Health Physics Society Web Site, August 2001.
6. **Zanzonico PB**. Response to "Ask-the-Expert" E Mail. Health Physics Society Web Site, January 2002.

7. **Zanzonico PB.** Response to "Ask-the-Expert" E Mail. Health Physics Society Web Site, May 2002.
8. **Zanzonico PB.** Response to "Ask-the-Expert" E Mail. Health Physics Society Web Site, April 2016.
9. Weber WA and **Zanzonico PB.** Reply: Eliminating use of the linear no-threshold assumption in medical imaging. J Nucl Med 58: 1015, 2017.

Pat Zanzonico

Pat Zanzonico, PhD

1/12/18
Date